MEDPACE
BIOANALYTICAL LABORATORIES

BIOANALYTICAL SAMPLE ANALYSIS REPORT

SAMPLE ANALYSIS OF LB-102 AND LB-101 IN HUMAN PLASMA SAMPLES FROM LB PHARMACEUTICALS, INC. CLINICAL STUDY LB-102-001

PREPARED BY: Shuming Yang, Ph.D.

TESTING SITE: Medpace Bioanalytical Laboratories

ADDRESS: 5365 Medpace Way
Cincinnati, OH 45227
USA

MBL PROJECT NO: MBL19315

MBL REPORT NO: RPT19315-SA1-1.0

SPONSOR: LB Pharmaceuticals, Inc.
575 Madison Avenue
New York, NY 10022
USA

Date of Current Version: 24-Aug-2020
Date of Original Version: 24-Aug-2020

REVISION HISTORY

VERSION DATE	REVISION HISTORY DETAILS
24-Aug-2020	First issuance of RPT19315-SA1-1.0

SIGNATURES

PREPARED BY

Shuming Yang — 24 Aug 2020

Shuming Yang, Ph.D.
Responsible Scientist
Medpace Bioanalytical Laboratories

Date

REVIEWED BY

24 Aug 2020

Tian-Sheng Lu, Ph.D.
Senior Director
Medpace Bioanalytical Laboratories

Date

Zachary Prensky — 8/21/20

Zachary Prensky
CEO
LB Pharmaceuticals, Inc.

Date

COMPLIANCE STATEMENT

This report represents data generated from the bioanalysis part of a clinical study. The sample analysis was conducted in accordance with the principles of Good Clinical Practices (GCP), United States Food and Drug Administration (FDA) Title 21 CFR Part 320 and current FDA and European Medicines Agency guidance on Bioanalytical Method Validation. No significant deviations affecting the quality, integrity, or interpretation of the study were known to occur. This report represents a true and accurate record of the results.

Shuming Yang

24 Aug 2020

Shuming Yang, Ph.D.
Responsible Scientist
Medpace Bioanalytical Laboratories (MBL)

Date

QUALITY ASSURANCE STATEMENT

The Medpace Quality Assurance Unit has conducted the following activities for this study:

Audit Date(s)	Phase Audited	Report Date to Responsible Scientist and MBL Management
22-24-Jul-2020	Data/Report	24-Jul-2020

This report is considered to accurately describe the procedures used in the study and the results obtained.

Erica Fehrenbach, B.S.
Quality Assurance Auditor
Medpace, Inc.

24 Aug 2020
Date

ARCHIVE STATEMENT

All study data including the report, study files, laboratory notebooks, instrument printouts, electronic data and other materials arising out of the study will be stored in the Medpace designated archive facility according to the current Standard Operating Procedures (SOPs) of Medpace Bioanalytical Laboratories SOP US-BL-12[1] for a maximum of three years. After that time, sponsor will be notified for the disposition.

Address of archive facility:

Access Information Protected (Retrievex)
690 E Crescentville Road
Cincinnati, OH 45246
USA
Tel: (513) 671-7717

PERSONNEL INVOLVED

The following personnel from Medpace Bioanalytical Laboratories were associated with various phases of the study:

Name	Role
Shuming Yang, Ph.D.	Responsible Scientist
Joshua Froning, B.S.	Contributing Scientist
Emily Epure, B.S.	Laboratory Technician
Morgan Weinberg, B.S.	Laboratory Technician

LIST OF ABBREVIATIONS

The following abbreviations may be used:

µg	Microgram(s)
µL	Microliter(s)
µm	Micrometer(s)
AD	Addendum
ALQ	Above Limit of Quantitation
BLQ	Below Limit of Quantitation
CFR	Code of Federal Regulations
Conc.	Concentration
CV	Coefficient of Variation
DQC	Dilution Quality Control Sample
EDTA	Ethylene Diamine Tetraacetic Acid
ESI	Electrospray Ionization
FDA	Food and Drug Administration (US)
F/T	Freeze/Thaw
GLP	Good Laboratory Practice
HPLC	High Performance Liquid Chromatography
HQC	High QC
hr	Hour
ICP-MS	Inductively Coupled Plasma Mass Spectrometry
ID	Identification Number
IS	Internal Standard
ISR	Incurred Sample Reanalysis
LC-MS/MS	Liquid Chromatography-Tandem Mass Spectrometry
LIMS	Laboratory Information Management System
LLOQ	Lower Limit of Quantitation
LQC	Low QC
M	Molar
m/z	Mass to Charge
MBL	Medpace Bioanalytical Laboratories
mg	Milligram(s)
min	Minute(s)
mL	Milliliter(s)
mm	Millimeter(s)
mM	Millimolar
MQC	Mid QC
MRM	Multiple Reaction Monitoring
MS	Mass Spectrometry
MV	Method Validation
N/A	Not Applicable
ng	Nanogram(s)
No.	Number
OECD	Organisation for Economic Co-operation and Development

pg	Picogram(s)
QC	Quality Control
r^2	Coefficient of Determination
RE	Relative Error
SA	Sample Analysis
S.D.	Standard Deviation
SOP	Standard Operating Procedure
Std/STD	Standard
ULOQ	Upper Limit of Quantitation

TABLE OF CONTENTS

LIST OF TABLES

LIST OF FIGURES

1. OBJECTIVE

The purpose of this bioanalytical part of the LB Pharmaceuticals clinical study LB-102-001 titled "A Randomized, Double-Blinded, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LB-102 Administered Orally to Healthy Subjects[2]" was to determine the concentrations of LB-102 and LB-101 in human plasma samples.

2. ANALYTICAL METHOD

Method Type:	LC-MS/MS
Matrix:	Human plasma (K_2EDTA as anticoagulant)
Instrument:	AB Sciex Triple Quad 5500 or QTRAP 5500 System
MS Type/Conditions:	ESI(+), MRM Transitions: m/z 384.1 → 256.1 (LB-102), 389.1 → 256.1 (IS, LB-102-d_5) 370.1 → 242.1 (LB-101), 375.1 → 242.1 (IS, LB-101-d_5)
Calibration Curve Range:	1.00 – 1000 ng/mL for LB-102 1.00 – 1000 ng/mL for LB-101
Column phase:	Reverse
Gradient:	10%-90%
Run Time:	~ 5.5 minutes
Sample Preparation:	The analytes were extracted from plasma samples by protein precipitation procedure. See MBL19314-M1.0[3] method for details.

3. SAMPLE INFORMATION

Sample Receipt Date	No. of Primary Samples	No. of Back Up Samples	Total Number of Samples Received
24-Jan-2020	128	0	128
06-Feb-2020	127	1	128
20-Feb-2020	129	126	255
05-Mar-2020	127	0	127
20-Apr-2020	128	0	128
04-May-2020	16	0	16
20-May-2020	272	0	272
08-Jun-2020	130	0	130
01-Jul-2020	268	0	268
06-Jul-2020	0	256	256
08-Jul-2020	0	271	271
10-Jul-2020	0	402	402
13-Jul-2020	0	264	264

All samples were received frozen on dry ice and stored at -70°C freezer (F1) before analysis

Date of first run of assay: 24-Jan-2020

Date of last run of assay: 06-Jul-2020

Total samples analyzed: 1325 plasma samples for LB-102 and LB-101

The longest storage duration of the samples received was 17 days. All samples were analyzed within the established long-term storage stability period of 63 days[4].

4. REFERENCE MATERIALS AND MATRIX

Calibration standards and quality control samples were prepared using the following reference materials and matrix in this sample analysis study phase:

Compound	Purpose	Source	Batch/Lot No.	Purity	Storage Conditions	Expiration/ Retest Date
LB-102 N-methyl amisulpride	Reference Standard	Kamtek, Inc.	0000259028	100%	Ambient	13-Jun-2020
LB-102-d_5	Internal Standard	Kamtek, Inc.	KXN-7091	97.0% chemical 99.3% isotopic	Ambient	02-Sep-2022
LB-101 Amisulpride icrom	Reference Standard	Kamtek, Inc.	M171758	100%	Ambient	31-July-2022
LB-101-d_5 (Amisulpride-d_5)	Internal Standard	Toronto Research Chemical	2-AMC-124-4	98.0% chemical 99.5% isotopic	-20°C	27-Sep-2022

Note: The stock solution concentrations were corrected for purity. All stock solutions of LB-102 were prepared prior to its expiration date of 13-Jun-2020.

Stock solutions in dimethyl sulfoxide used during sample analysis were prepared on 06-Jan-2020, 10-Mar-2020 and 18-May-2020; these are stable for 64 days at -20°C (see RPT19314-MV1-1.0[4] for description). Working solutions in 0.1% formic acid in acetonitrile: water (50:50) were prepared on 06-Jan-2020, 10-Mar-2020 and 18-May-2020. Calibration standards and quality control samples were freshly prepared for each run (see Table 1 for dates).

The matrix used in this sample analysis study phase was human K_2EDTA plasma. Source information and batch/lot number of the control human plasma were kept in the study file at Medpace.

Matrix Type	Biological Matrix ID No.	Receipt Date
Plasma	HMN15384	15-Mar-2019
	HMN15389	15-Mar-2019
	HMN86497	01-Aug-2019
	HMN86498	01-Aug-2019
	HMN86499	01-Aug-2019
	HMN200418	03-Dec-2019
	HMN200420	03-Dec-2019

5. ANALYTICAL RESULTS

Sample analysis is guided by MBL SOP US-BL-40[5]. The analytical run dates and the status for each of the sample analysis runs are summarized in Table 1.

Peak area integrations were performed using Analyst software (version 1.6.3) from Applied Biosystems. Filenames and peak areas were electronically transferred and peak area ratios and concentrations were calculated in Watson LIMS software (version 7.4.2).

Statistical calculations in the report tables were calculated from unrounded concentration values taken directly from the raw data. The concentration values appearing in the report tables may have been rounded for display purposes. All temperatures are nominal settings.

The following naming conventions have been used on chromatograms:

Standard: Run No. + Injection No. + Study No. + STD ID + Replicate No. + Dilution Factor

QC: Run No. + Injection No. + Study No. + QC ID + Replicate No. + Dilution Factor

Subject Sample: Run No. + Injection No. + Study No. + Subject ID + Treatment + Time + Matrix-Split + Dilution Factor

5.1 Calibration Curve Data

A typical calibration curve for LB-102 in human plasma is presented in Figure 1. Back-calculated concentrations for LB-102 calibration standards in human plasma are presented in Table 2. The calibration curve parameters for LB-102 in human plasma are presented in Table 3. The coefficients of determination (r^2) are ≥0.9977 for LB-102 for all analytical runs. The data showed a good linearity for LB-102 in the range of 1.00 – 1000 ng/mL.

A typical calibration curve for LB-101 in human plasma is presented in Figure 2. Back-calculated concentrations for LB-101 calibration standards in human plasma are presented in Table 4. The calibration curve parameters for LB-101 in human plasma are presented in Table 5. The coefficients of determination (r^2) are ≥0.9975 for LB-101 for all analytical runs. The data showed a good linearity for LB-101 in the range of 1.00 – 1000 ng/mL.

5.2 Quality Control (QC) Sample Data

Results from the quality control samples for LB-102 concurrently ran with the study plasma samples are presented in Table 6. Overall CV, which is an expression of the precision, was ≤3.5% for LB-102 LQC, MQC and HQC samples. The overall RE, which is an expression of the accuracy, was from 1.0% to 2.4% for LB-102 LQC, MQC and HQC samples. The 10-fold dilution QC samples showed the overall CV of 0.2% and the overall RE of -11.6%. The results showed that the assay method is precise and accurate for the quantitation of LB-102 in human plasma samples, and a 10-fold dilution factor can be used for the assay of samples with concentration values over the calibration curve.

Example chromatograms of control plasma blank, blank with internal standard, the lowest standard (LLOQ) samples, the highest standard (ULOQ) samples, LQC, MQC and HQC samples for LB-102 in human plasma are presented in Figure 3 to Figure 9. The precision and accuracy

results for the QC samples of LB-102 from all analytical runs are also represented in Figure 17 to Figure 19.

Results from the quality control samples for LB-101 concurrently ran with the study plasma samples are presented in Table 7. The overall CV was ≤3.4% for LB-101 LQC, MQC and HQC samples. The overall RE was from 1.3% to 3.5% for LB-101 LQC, MQC and HQC samples. The 10-fold dilution QC samples showed the overall CV of 0.3% and the overall RE of -12.2%. The results showed that the assay method is precise and accurate for the quantitation of LB-101 in human plasma samples, and a 10-fold dilution factor can be used for the assay of samples with concentration values over the calibration curve.

Example chromatograms of control plasma blank, blank with internal standard, the lowest standard (LLOQ) samples, the highest standard (ULOQ) samples, LQC, MQC and HQC samples for LB-101 in human plasma are presented in Figure 10 to Figure 16. The precision and accuracy results for the QC samples of LB-101 from all analytical runs are also represented in Figure 20 to Figure 22.

5.3 Matrix Interference

The potential for interference from matrix components was tested in each run using an extracted blank plasma sample and a blank with IS plasma sample for LB-102 (Figure 3 and Figure 4, respectively) and LB-101 (Figure 10 and Figure 11, respectively). There was no obvious interference observed in any of the sample analysis runs.

5.4 Drug Concentration Data

The concentrations of LB-102 and LB-101 in the study plasma samples from the Study LB-102-001 are provided in Table 8.

Example chromatograms of LB-102 and LB-101 in study plasma samples from Subject 2093, D1 pre-dose through D9 48hr and Subject 2094, D1 pre-dose through D6, 16hr are presented in Figure 23 to Figure 154.

5.5 Re-assay or Reinjection of Samples

Sample re-assay due to analytical reasons is guided by MBL SOP US-BL-41[6]. Samples for LB-102 that required re-assay in this study are listed in Table 9. Samples for LB-101 that required re-assay in this study are listed in Table 10.

Sample reinjection is guided by MBL SOP US-BL-40[5]. Samples for LB-102 and LB-101 that required reinjection are described in Section 6.

5.6 Incurred Sample Reanalysis (ISR)

The results of the incurred sample reanalysis were calculated by the equation:

% Difference = (Reanalysis Conc. – Original Conc.) / (Mean of Original Conc. + Reanalysis Conc.) × 100 %

A total of 132 plasma samples were selected for LB-102 and LB-101 reanalysis.

The ISR results of LB-102 in plasma are presented in Table 11. The results showed that 100% (132 of 132) of the re-assayed results agreed within ±20% of the mean results.

The ISR results of LB-101 in plasma are presented in Table 12. The results showed that 100% (132 of 132) of the re-assayed results agreed within ±20% of the mean results.

The ISR results met the acceptance criteria as pre-defined in MBL SOP US-BL-47[7], Incurred Sample Reanalysis, indicating the LC-MS/MS method is reproducible.

6. DEVIATIONS/UNEXPECTED EVENTS

No deviations from the clinical protocol or SOPs were observed in this sample analysis phase.

The solvent blank and double blank samples in Run 15 contained a small peak at the position of LB-101-d_5. The peaks were less than 5% of the internal standard peaks.

In Run 17, peak splitting was noted on injection 64 and column deterioration was suspected. The column was replaced and the run was restarted at injection 55.

The solvent blank and double blank samples in Run 19 contained a small peak at the position of LB-101-d_5. The peaks were less than 2% of the internal standard peaks.

Samples for Day 2 24hr and Day 3 48hr for Cohort 8 were updated to Day 2 pre-dose (0hr) and Day 3 pre-dose (0hr) by data management. The samples had already been analyzed using the previous designation. The samples are reported in Table 8 as Day 2 24hr and Day 3 48hr and marked with a footnote that provides the corrected sample names.

None of these unexpected events impacted the integrity of the study data.

7. REFERENCES

1) MBL SOP US-BL-12: Archiving Procedures

2) Study Protocol and Amendments

    a. A Randomized, Double-Blinded, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LB-102 Administered Orally to Healthy Subjects, Version 5

3) An LC-MS/MS Assay for the Determination of LB-102 and LB-101 in Human K_2EDTA Plasma, MBL Method No. MBL19314-M1.0, Medpace Bioanalytical Laboratories, Cincinnati, OH, USA

4) Validation of an LC-MS/MS Method for the Quantitative Determination of LB-102 and LB-101 in Human K_2EDTA Plasma, MBL Report No. RPT19314-MV1-1.0, Medpace Bioanalytical Laboratories, Cincinnati, OH, USA

5) MBL SOP US-BL-40: Bioanalytical Sample Analysis

6) MBL SOP US-BL-41: Guidance for Reanalysis and the Interpretation of Study Sample Results

7) MBL SOP US-BL-47: Incurred Sample Reanalysis

8. TABLES

Table 1: Summary of Analytical Runs for LB-102 and LB-101 in Human Plasma

Run Date	Instrument ID	Run Number	Analytical Run Description	Status
24-Jan-2020	*	1	Analysis of 64 samples	Accepted
25-Jan-2020	*	2	Analysis of 64 samples	Accepted
27-Jan-2020	*	3	Re-assay and Incurred Sample Reanalysis	Accepted
06-Feb-2020	*	4	Analysis of 64 samples	Accepted
07-Feb-2020	*	5	Analysis of 64 samples	Accepted
20-Feb-2020	*	6	Analysis of 64 samples	Accepted
21-Feb-2020	*	7	Analysis of 64 samples	Accepted
05-Mar-2020	*	8	Analysis of 64 samples	Accepted
06-Mar-2020	*	9	Analysis of 63 samples	Accepted
06-Mar-2020	*	10	Dilution samples	Accepted
09-Mar-2020	*	11	Incurred Sample Reanalysis	Accepted
20-Apr-2020	*	12	Analysis of 64 samples	Accepted
21-Apr-2020	*	13	Analysis of 64 samples	Accepted
21-Apr-2020	*	14	Re-assay	Accepted
04-May-2020	*	15	Analysis of 16 samples	Accepted
20-May-2020	*	16	Analysis of 68 samples	Accepted
21-May-2020	*	17[a]	Analysis of 68 samples	Accepted
21-May-2020	*	18	Analysis of 68 samples	Accepted
22-May-2020	*	19	Analysis of 68 samples	Accepted
09-Jun-2020	*	20	Analysis of 66 samples	Accepted
10-Jun-2020	*	21	Analysis of 64 samples	Accepted
01-Jul-2020	*	22	Analysis of 72 samples	Accepted
02-Jul-2020	*	23	Analysis of 52 samples	Accepted
02-Jul-2020	*	24	Analysis of 72 samples	Accepted
02-Jul-2020	*	25	Analysis of 72 samples	Accepted
06-Jul-2020	*	26	Incurred Sample Reanalysis	Accepted

* MBLUS-Triple Quad 5500F

[a] Peak splitting was noted at injection 64 of Run 17. The column was replaced and the run was restarted at injection 55.

Table 2: Back-calculated Concentrations for LB-102 Calibration Standards in Human Plasma

Assay Date	Analytical Run Number	LB-102 Nominal Concentrations (ng/mL)							
		1.00	2.00	5.00	20.0	100	400	800	1000
		LB-102 Measured Concentrations (ng/mL)[a]							
24-Jan-2020	1	0.993	2.01	5.11	19.9	100	410	788	1000
		1.01	1.97	5.05	20.0	98.9	408	787	983
25-Jan-2020	2	0.987	1.98	5.07	20.3	101	407	769	1020
		1.03	1.93	5.05	20.0	98.5	409	786	993
27-Jan-2020	3	0.999	1.97	4.91	19.7	102	405	793	979
		1.00	2.03	5.03	20.4	101	411	791	982
06-Feb-2020	4	0.935	2.05	5.06	19.7	101	395	816	999
		1.05	2.03	4.85	20.5	98.8	399	798	988
07-Feb-2020	5	1.01	2.08	5.04	20.2	101	402	804	987
		0.967	2.02	4.98	19.8	98.7	397	787	995
20-Feb-2020	6	1.01	1.96	4.95	20.2	99.2	406	796	1010
		1.01	1.96	5.01	20.5	101	395	787	1000
21-Feb-2020	7	1.03	1.98	4.99	20.9	102	399	785	968
		0.998	1.88	4.95	20.3	102	393	815	995
05-Mar-2020	8	1.01	2.01	4.93	20.0	99.3	398	809	1030
		1.01	1.94	4.92	19.7	98.9	401	806	1020
06-Mar-2020	9	0.976	1.99	4.92	19.4	97.7	400	812	1010
		1.00	2.11	5.04	19.6	98.4	402	810	1020
06-Mar-2020	10	0.958	2.14	4.92	19.0	104	392	771	1030
		0.996	2.06	5.15	19.2	104	388	785	1020
09-Mar-2020	11	0.955	1.97	4.82	19.2	96.8	403	823	1060
		1.05	2.11	4.65	19.2	100	399	815	1050
20-Apr-2020	12	1.02	2.09	5.09	20.0	98.8	375	830	1030
		0.963	1.93	5.05	20.3	99.3	382	807	1010
21-Apr-2020	13	0.975	2.02	5.03	19.9	97.0	385	819	1030
		0.989	2.11	5.07	19.6	98.0	382	812	1030
21-Apr-2020	14	1.01	2.05	5.00	20.1	99.3	402	787	1000
		0.978	1.99	5.15	19.9	99.3	401	791	1000
04-May-2020	15	1.01	1.94	5.12	19.4	99.7	402	797	1030
		1.00	1.98	5.02	19.7	100	404	784	1010
20-May-2020	16	0.992	1.85	4.94	19.8	98.8	403	801	993
		1.05	2.01	4.98	20.2	103	405	808	1010
21-May-2020	17	0.995	2.00	4.99	20.2	101	400	805	1010
		1.03	1.89	5.01	20.2	99.9	392	808	999
21-May-2020	18	0.995	2.02	4.87	20.6	99.5	409	808	991
		1.04	1.90	4.72	20.4	98.1	411	810	997
22-May-2020	19	1.00	1.99	4.92	20.5	96.2	402	803	997
		0.975	2.15	4.76	20.7	98.1	398	805	1010
09-Jun-2020	20	1.01	2.02	4.81	20.0	100	388	805	1030

Assay Date	Analytical Run Number	LB-102 Nominal Concentrations (ng/mL)							
		1.00	2.00	5.00	20.0	100	400	800	1000
		LB-102 Measured Concentrations (ng/mL)[a]							
		0.984	2.03	4.96	20.5	99.7	385	811	1020
10-Jun-2020	21	1.02	1.98	4.70	19.8	100	396	820	1040
		1.02	1.98	4.78	20.2	101	399	800	1030
01-Jul-2020	22	1.00	1.90	5.05	19.8	98.6	411	789	1010
		1.02	2.04	4.82	20.2	102	399	791	1010
02-Jul-2020	23	1.03	1.84	5.00	20.2	97.2	402	792	1010
		0.999	2.07	4.90	19.9	97.2	415	813	1030
02-Jul-2020	24	0.979	1.97	5.10	19.6	103	402	784	999
		1.03	1.99	4.98	19.9	99.9	407	795	996
02-Jul-2020	25	1.05	1.91	5.19	19.3	99.9	391	804	1020
		0.995	1.87	5.06	20.3	99.8	401	805	1020
06-Jul-2020	26	1.00	1.91	4.86	20.0	97.8	399	828	1000
		1.04	1.95	4.99	19.6	100	409	828	1010
	Mean	1.00	1.99	4.97	20.0	99.7	400	801	1010
	S.D.	0.0256	0.0721	0.119	0.419	1.76	8.39	14.0	18.4
	%CV	2.6	3.6	2.4	2.1	1.8	2.1	1.7	1.8
	%RE	0.0	-0.5	-0.6	0.0	-0.3	0.0	0.1	1.0
	n	52	52	52	52	52	52	52	52

[a] A linear regression method was used with 1/concentration^2 as the weighting factor.

Table 3: Calibration Curve Parameters for LB-102

Run Date	Curve Number[a]	Slope	Intercept	r^2
24-Jan-2020	1	0.0436	0.000219	0.9997
25-Jan-2020	2	0.0430	0.00162	0.9994
27-Jan-2020	3	0.0436	0.00148	0.9997
06-Feb-2020	4	0.0431	0.00126	0.9991
07-Feb-2020	5	0.0434	-0.000774	0.9996
20-Feb-2020	6	0.0427	0.00307	0.9998
21-Feb-2020	7	0.0425	0.00137	0.9991
05-Mar-2020	8	0.0423	0.00154	0.9997
06-Mar-2020	9	0.0425	0.00372	0.9994
06-Mar-2020	10	0.0422	0.00347	0.9982
09-Mar-2020	11	0.0428	0.000945	0.9977
20-Apr-2020	12	0.0436	0.00277	0.9987
21-Apr-2020	13	0.0436	0.00162	0.9989
21-Apr-2020	14	0.0421	0.00302	0.9998
04-May-2020	15	0.0422	0.000782	0.9996
20-May-2020	16	0.0489	0.00401	0.9992
21-May-2020	17	0.0489	0.00406	0.9996
21-May-2020	18	0.0489	0.00671	0.9990
22-May-2020	19	0.0495	0.00371	0.9989
09-Jun-2020	20	0.0494	0.000601	0.9994
10-Jun-2020	21	0.0493	0.00478	0.9991
01-Jul-2020	22	0.0518	0.00290	0.9994
02-Jul-2020	23	0.0517	0.00430	0.9988
02-Jul-2020	24	0.0525	0.00269	0.9996
02-Jul-2020	25	0.0526	0.00223	0.9988
06-Jul-2020	26	0.0531	0.00195	0.9992
Mean		0.0461	0.00246	0.9992
S.D.		0.00406	0.00164	0.0005
n		26	26	26

[a] A linear regression method was used with 1/concentration^2 as the weighting factor.

Table 4: Back-calculated Concentrations for LB-101 Calibration Standards in Human Plasma

Assay Date	Analytical Run Number	LB-101 Nominal Concentrations (ng/mL)							
		1.00	2.00	5.00	20.0	100	400	800	1000
		LB-101 Measured Concentrations (ng/mL)[a]							
24-Jan-2020	1	1.02	1.95	5.03	20.1	98.8	411	783	991
		1.01	1.89	5.10	20.3	103	404	794	988
25-Jan-2020	2	0.990	1.98	5.02	19.7	99.1	412	787	1010
		1.03	1.97	4.94	20.3	99.6	398	808	1010
27-Jan-2020	3	1.03	1.94	5.00	20.0	100	399	794	1010
		1.01	1.93	4.98	20.1	101	404	795	1010
06-Feb-2020	4	0.969	2.01	5.04	19.7	102	402	811	1000
		1.03	2.01	5.01	19.3	97.3	403	808	1010
07-Feb-2020	5	0.972	2.03	4.92	20.0	100	395	809	990
		1.01	2.08	4.98	20.3	100	399	804	982
20-Feb-2020	6	0.966	1.89	5.02	20.3	104	390	788	971
		1.06	2.00	4.95	20.5	101	396	827	995
21-Feb-2020	7	0.981	1.94	5.01	20.4	103	389	802	1010
		1.04	1.97	4.96	20.9	100	394	776	990
05-Mar-2020	8	0.980	1.93	4.87	19.9	101	404	819	1040
		1.03	2.11	4.79	19.8	98.0	399	793	1020
06-Mar-2020	9	0.981	2.04	5.04	19.0	98.1	402	816	1020
		0.978	2.15	4.89	19.7	100	400	791	1000
06-Mar-2020	10	0.950	1.92	5.10	19.0	106	391	774	1000
		1.06	1.99	5.26	19.6	106	392	752	1050
09-Mar-2020	11	0.988	1.92	4.81	19.9	101	396	792	1030
		1.02	2.13	4.85	19.4	97.5	403	814	1060
20-Apr-2020	12	1.09	1.91	5.19	20.1	97.6	380	820	1040
		0.928	1.99	4.96	20.1	98.5	379	815	1050
21-Apr-2020	13	1.00	1.92	5.13	20.0	100	378	836	1030
		1.03	1.92	5.13	20.0	98.9	381	809	1020
21-Apr-2020	14	1.02	2.02	5.08	20.0	99.5	404	815	991
		0.974	1.99	5.06	19.9	99.4	401	796	973
04-May-2020	15	0.965	1.92	5.00	20.1	99.1	402	782	1010
		1.04	2.08	4.98	19.7	100	403	793	1030
20-May-2020	16	1.00	2.02	4.82	20.0	100	399	792	998
		1.01	1.94	5.08	20.1	101	400	808	1010
21-May-2020	17	0.974	1.81	4.99	19.7	99.9	403	797	1020
		1.05	2.11	5.02	20.0	101	402	799	1000
21-May-2020	18	0.983	2.04	4.81	20.6	97.5	403	816	1000
		1.03	1.97	4.75	20.7	97.4	408	816	989
22-May-2020	19	1.02	1.99	4.83	21.3	101	406	807	1000
		1.01	1.95	4.68	20.4	95.8	399	816	1000
09-Jun-2020	20	0.987	1.86	4.65	20.4	101	391	800	1030

Assay Date	Analytical Run Number	LB-101 Nominal Concentrations (ng/mL)							
		1.00	**2.00**	**5.00**	**20.0**	**100**	**400**	**800**	**1000**
		LB-101 Measured Concentrations (ng/mL)[a]							
		1.05	2.02	5.14	19.9	99.6	404	799	1030
10-Jun-2020	21	1.02	1.96	5.02	20.3	100	390	807	1020
		1.01	1.95	4.71	20.3	102	397	804	1010
01-Jul-2020	22	0.960	2.12	4.88	19.9	96.5	401	785	994
		0.996	2.07	5.08	19.9	99.7	409	786	1020
02-Jul-2020	23	1.03	1.99	5.05	20.1	98.9	396	789	979
		0.961	1.99	5.20	19.6	98.0	415	785	1030
02-Jul-2020	24	1.06	2.08	5.12	19.4	99.9	398	821	1000
		0.911	2.06	4.81	19.3	98.4	405	811	1010
02-Jul-2020	25	0.976	2.06	5.15	19.3	101	404	790	967
		1.02	1.92	5.13	19.0	102	404	802	1030
06-Jul-2020	26	0.963	1.86	5.03	20.1	99.8	396	808	1000
		1.07	2.06	4.78	19.7	100	395	843	1020
	Mean	1.00	1.99	4.98	20.0	100	399	802	1010
	S.D.	0.0367	0.0754	0.140	0.460	2.04	7.92	16.1	20.5
	%CV	3.7	3.8	2.8	2.3	2.0	2.0	2.0	2.0
	%RE	0.0	-0.5	-0.4	0.0	0.0	-0.3	0.3	1.0
	n	52	52	52	52	52	52	52	52

[a] A linear regression method was used with 1/concentration^2 as the weighting factor.

Table 5: Calibration Curve Parameters for LB-101

Run Date	Curve Number[a]	Slope	Intercept	r^2
24-Jan-2020	1	0.0432	0.000902	0.9993
25-Jan-2020	2	0.0430	0.00179	0.9997
27-Jan-2020	3	0.0437	0.00186	0.9997
06-Feb-2020	4	0.0428	0.00233	0.9996
07-Feb-2020	5	0.0431	0.000261	0.9997
20-Feb-2020	6	0.0425	0.000226	0.9988
21-Feb-2020	7	0.0421	-0.000563	0.9992
05-Mar-2020	8	0.0409	0.00216	0.9990
06-Mar-2020	9	0.0417	0.000966	0.9990
06-Mar-2020	10	0.0415	0.00296	0.9975
09-Mar-2020	11	0.0421	0.00127	0.9987
20-Apr-2020	12	0.0402	0.00204	0.9975
21-Apr-2020	13	0.0400	0.00295	0.9987
21-Apr-2020	14	0.0391	0.00284	0.9997
04-May-2020	15	0.0383	0.00110	0.9993
20-May-2020	16	0.0403	0.000595	0.9997
21-May-2020	17	0.0401	0.00283	0.9986
21-May-2020	18	0.0408	0.000728	0.9991
22-May-2020	19	0.0400	0.00168	0.9988
09-Jun-2020	20	0.0409	0.000546	0.9986
10-Jun-2020	21	0.0413	0.00148	0.9994
01-Jul-2020	22	0.0441	0.00205	0.9991
02-Jul-2020	23	0.0444	0.000747	0.9992
02-Jul-2020	24	0.0444	0.00280	0.9982
02-Jul-2020	25	0.0443	-0.00196	0.9989
06-Jul-2020	26	0.0452	0.00193	0.9984
Mean		0.0419	0.00140	0.9990
S.D.		0.00183	0.00118	0.0006
n		26	26	26

[a] A linear regression method was used with 1/concentration^2 as the weighting factor.

Table 6: Analytical Performance of LB-102 Quality Control Samples in Human Plasma

Run Date	Run Number	LB-102 Nominal Concentrations (ng/mL)			
		LQC (3.00)	MQC (30.0)	HQC (750)	DQC (5000)
		LB-102 Measured Concentrations (ng/mL)			
24-Jan-2020	1	3.04	30.6	736	N/A
		2.95	30.0	775	N/A
25-Jan-2020	2	3.10	30.5	761	N/A
		3.06	30.8	750	N/A
27-Jan-2020	3	2.98	30.2	766	N/A
		2.92	29.4	732	N/A
06-Feb-2020	4	3.14	29.3	733	N/A
		3.07	30.7	743	N/A
07-Feb-2020	5	3.17	30.0	750	N/A
		3.08	29.8	742	N/A
20-Feb-2020	6	2.86	29.8	763	N/A
		3.05	29.7	767	N/A
21-Feb-2020	7	3.05	29.9	766	N/A
		3.06	29.9	779	N/A
05-Mar-2020	8	3.03	30.2	757	N/A
		2.99	30.0	755	N/A
06-Mar-2020	9	2.89	31.0	761	N/A
		2.84	29.0	748	N/A
06-Mar-2020	10	3.00	29.9	774	4420
		3.03	29.2	780	4410
09-Mar-2020	11	3.03	29.2	767	N/A
		3.08	30.0	760	N/A
20-Apr-2020	12	2.77	28.8	742	N/A
		2.86	29.3	741	N/A
21-Apr-2020	13	2.76	28.5	739	N/A
		2.94	29.0	741	N/A
21-Apr-2020	14	2.96	29.3	729	N/A
		2.95	29.5	727	N/A
04-May-2020	15	2.92	28.7	753	N/A
		3.07	28.6	741	N/A
20-May-2020	16	3.05	31.3	800	N/A
		3.11	30.7	798	N/A
21-May-2020	17	3.03	31.5	791	N/A
		3.22	31.4	789	N/A
21-May-2020	18	3.05	30.6	772	N/A
		3.12	32.0	783	N/A
22-May-2020	19	3.07	31.1	766	N/A
		3.27	30.7	776	N/A
09-Jun-2020	20	3.13	31.3	787	N/A

Run Date	Run Number	LB-102 Nominal Concentrations (ng/mL) LQC (3.00)	MQC (30.0)	HQC (750)	DQC (5000)
		LB-102 Measured Concentrations (ng/mL)			
		3.17	31.2	788	N/A
10-Jun-2020	21	3.00	30.7	800	N/A
		2.92	31.7	798	N/A
01-Jul-2020	22	3.07	32.4	794	N/A
		3.13	32.4	804	N/A
02-Jul-2020	23	3.11	31.7	785	N/A
		2.99	32.3	809	N/A
02-Jul-2020	24	3.14	30.9	786	N/A
		2.91	30.9	787	N/A
02-Jul-2020	25	3.07	31.0	795	N/A
		3.12	31.7	790	N/A
06-Jul-2020	26	3.04	31.0	781	N/A
		3.18	30.5	775	N/A
Overall Mean		3.03	30.4	768	4420
Overall S.D.		0.107	1.03	22.5	7.07
Overall %CV		3.5	3.4	2.9	0.2
Overall %RE		1.0	1.3	2.4	-11.6
n		52	52	52	2

Table 7: Analytical Performance of LB-101 Quality Control Samples in Human Plasma

Run Date	Run Number	LB-101 Nominal Concentrations (ng/mL)			
		LQC (3.00)	MQC (30.0)	HQC (750)	DQC (5000)
		LB-101 Measured Concentrations (ng/mL)			
24-Jan-2020	1	3.12	30.9	771	N/A
		3.07	30.8	768	N/A
25-Jan-2020	2	3.11	30.8	785	N/A
		3.01	31.0	765	N/A
27-Jan-2020	3	3.03	30.7	755	N/A
		2.94	29.5	760	N/A
06-Feb-2020	4	3.07	29.7	760	N/A
		3.08	30.7	770	N/A
07-Feb-2020	5	2.98	29.6	736	N/A
		3.03	30.1	762	N/A
20-Feb-2020	6	2.97	30.3	776	N/A
		3.12	30.3	771	N/A
21-Feb-2020	7	3.08	30.0	777	N/A
		3.01	31.0	809	N/A
05-Mar-2020	8	3.03	30.3	795	N/A
		2.98	29.6	779	N/A
06-Mar-2020	9	3.11	29.9	778	N/A
		2.94	29.2	756	N/A
06-Mar-2020	10	2.97	29.8	756	4380
		2.98	30.4	777	4400
09-Mar-2020	11	2.93	29.3	754	N/A
		3.00	29.4	778	N/A
20-Apr-2020	12	2.98	29.3	762	N/A
		2.99	28.8	753	N/A
21-Apr-2020	13	2.79	29.3	762	N/A
		2.95	29.4	752	N/A
21-Apr-2020	14	2.86	29.8	735	N/A
		2.90	29.1	724	N/A
04-May-2020	15	2.96	28.7	753	N/A
		3.11	29.2	735	N/A
20-May-2020	16	3.10	31.3	797	N/A
		3.26	30.3	793	N/A
21-May-2020	17	3.11	32.7	794	N/A
		3.10	31.2	818	N/A
21-May-2020	18	3.09	30.7	783	N/A
		3.28	30.8	799	N/A
22-May-2020	19	3.13	30.8	773	N/A
		3.11	31.7	800	N/A
09-Jun-2020	20	3.23	31.2	799	N/A

Run Date	Run Number	LB-101 Nominal Concentrations (ng/mL) LQC (3.00)	MQC (30.0)	HQC (750)	DQC (5000)
		LB-101 Measured Concentrations (ng/mL)			
		3.08	31.7	796	N/A
10-Jun-2020	21	3.14	31.6	799	N/A
		3.19	30.2	798	N/A
01-Jul-2020	22	3.17	30.9	798	N/A
		2.95	31.0	778	N/A
02-Jul-2020	23	3.13	30.9	798	N/A
		3.08	31.1	777	N/A
02-Jul-2020	24	3.33	30.5	769	N/A
		3.07	31.3	791	N/A
02-Jul-2020	25	3.16	31.1	803	N/A
		3.00	31.6	786	N/A
06-Jul-2020	26	3.13	32.1	803	N/A
		3.01	30.8	793	N/A
Overall Mean		3.06	30.4	776	4390
Overall S.D.		0.105	0.893	21.2	14.1
Overall %CV		3.4	2.9	2.7	0.3
Overall %RE		2.0	1.3	3.5	-12.2
n		52	52	52	2

Table 8: Concentration Results of LB-102 and LB-101 in Human Plasma Samples

Subject ID	Treatment ID	Study Day	Nominal Time (hr)	LB-102 Conc. (ng/mL)	LB-101 Conc. (ng/mL)
0001	1	1	0	BLQ	BLQ
0001	1	1	0.25	BLQ	BLQ
0001	1	1	0.50	BLQ	BLQ
0001	1	1	0.75	BLQ	BLQ
0001	1	1	1	BLQ	BLQ
0001	1	1	1.5	BLQ	BLQ
0001	1	1	2	BLQ	BLQ
0001	1	1	3	BLQ	BLQ
0001	1	1	4	BLQ	BLQ
0001	1	1	6	BLQ	BLQ
0001	1	1	8	BLQ	BLQ
0001	1	1	12	BLQ	BLQ
0001	1	1	16	BLQ	BLQ
0001	1	2	24	BLQ	BLQ
0001	1	2	32	BLQ	BLQ
0001	1	3	48	BLQ	BLQ
0002	1	1	0	BLQ	BLQ
0002	1	1	0.25	9.16	BLQ
0002	1	1	0.50	51.3	BLQ
0002	1	1	0.75	53.9	BLQ
0002	1	1	1	48.3	BLQ
0002	1	1	1.5	49.6	BLQ
0002	1	1	2	75.3	BLQ
0002	1	1	3	153	1.16
0002	1	1	4	138	1.13
0002	1	1	6	111	1.01
0002	1	1	8	82.3	BLQ
0002	1	1	12	51.8	BLQ
0002	1	1	16	32.7	BLQ
0002	1	2	24	17.9	BLQ
0002	1	2	32	10.2	BLQ
0002	1	3	48	4.53	BLQ
0003	1	1	0	BLQ	BLQ
0003	1	1	0.25	BLQ	BLQ
0003	1	1	0.50	62.9	BLQ
0003	1	1	0.75	67.4	1.35
0003	1	1	1	80.6	1.98
0003	1	1	1.5	112	2.71
0003	1	1	2	103	2.45

Subject ID	Treatment ID	Study Day	Nominal Time (hr)	LB-102 Conc. (ng/mL)	LB-101 Conc. (ng/mL)
0003	1	1	3	173	3.99
0003	1	1	4	156	3.78
0003	1	1	6	110	2.98
0003	1	1	8	78.2	2.13
0003	1	1	12	52.4	1.91
0003	1	1	16	26.8	1.13
0003	1	2	24	10.7	BLQ
0003	1	2	32	5.01	BLQ
0003	1	3	48	1.79	BLQ
0004	1	1	0	BLQ	BLQ
0004	1	1	0.25	BLQ	BLQ
0004	1	1	0.50	8.18	BLQ
0004	1	1	0.75	49.5	BLQ
0004	1	1	1	70.4	1.80
0004	1	1	1.5	61.9	2.02
0004	1	1	2	97.3	2.52
0004	1	1	3	224	6.27
0004	1	1	4	172	5.01
0004	1	1	6	105	3.68
0004	1	1	8	67.2	2.90
0004	1	1	12	33.7	1.72
0004	1	1	16	20.5	1.26
0004	1	2	24	10.8	BLQ
0004	1	2	32	6.50	BLQ
0004	1	3	48	2.91	BLQ
0005	1	1	0	BLQ	BLQ
0005	1	1	0.25	BLQ	BLQ
0005	1	1	0.50	13.5	BLQ
0005	1	1	0.75	18.3	BLQ
0005	1	1	1	47.2	1.15
0005	1	1	1.5	53.2	1.84
0005	1	1	2	57.5	2.00
0005	1	1	3	91.6	2.63
0005	1	1	4	143	4.54
0005	1	1	6	102	3.52
0005	1	1	8	77.2	3.09
0005	1	1	12	40.5	1.96
0005	1	1	16	25.7	1.47
0005	1	2	24	16.5	1.01
0005	1	2	32	12.2	BLQ

Subject ID	Treatment ID	Study Day	Nominal Time (hr)	LB-102 Conc. (ng/mL)	LB-101 Conc. (ng/mL)
0005	1	3	48	5.56	BLQ
0007	1	1	0	BLQ	BLQ
0007	1	1	0.25	BLQ	BLQ
0007	1	1	0.50	BLQ	BLQ
0007	1	1	0.75	BLQ	BLQ
0007	1	1	1	BLQ	BLQ
0007	1	1	1.5	292	6.47
0007	1	1	2	BLQ	BLQ
0007	1	1	3	BLQ	BLQ
0007	1	1	4	BLQ	BLQ
0007	1	1	6	BLQ	BLQ
0007	1	1	8	BLQ	BLQ
0007	1	1	12	BLQ	BLQ
0007	1	1	16	BLQ	BLQ
0007	1	2	24	BLQ	BLQ
0007	1	2	32	BLQ	BLQ
0007	1	3	48	BLQ	BLQ
0008	1	1	0	BLQ	BLQ
0008	1	1	0.25	1.20	BLQ
0008	1	1	0.50	42.3	BLQ
0008	1	1	0.75	62.8	1.14
0008	1	1	1	152	3.06
0008	1	1	1.5	70.9	1.14
0008	1	1	2	252	7.28
0008	1	1	3	201	5.80
0008	1	1	4	159	5.03
0008	1	1	6	99.5	3.71
0008	1	1	8	70.0	2.76
0008	1	1	12	40.6	1.89
0008	1	1	16	27.9	1.40
0008	1	2	24	19.1	BLQ
0008	1	2	32	10.8	BLQ
0008	1	3	48	5.27	BLQ
0010	1	1	0	BLQ	BLQ
0010	1	1	0.25	BLQ	BLQ
0010	1	1	0.50	24.5	BLQ
0010	1	1	0.75	68.3	BLQ
0010	1	1	1	66.3	BLQ
0010	1	1	1.5	BLQ	BLQ
0010	1	1	2	55.8	1.05

Subject ID	Treatment ID	Study Day	Nominal Time (hr)	LB-102 Conc. (ng/mL)	LB-101 Conc. (ng/mL)
0010	1	1	3	111	1.44
0010	1	1	4	111	1.76
0010	1	1	6	82.0	1.50
0010	1	1	8	62.7	1.49
0010	1	1	12	35.8	BLQ
0010	1	1	16	25.4	BLQ
0010	1	2	24	14.2	BLQ
0010	1	2	32	8.73	BLQ
0010	1	3	48	3.31	BLQ
0028	2	1	0	BLQ	BLQ
0028	2	1	0.25	BLQ	BLQ
0028	2	1	0.50	BLQ	BLQ
0028	2	1	0.75	BLQ	BLQ
0028	2	1	1	BLQ	BLQ
0028	2	1	1.5	BLQ	BLQ
0028	2	1	2	BLQ	BLQ
0028	2	1	3	BLQ	BLQ
0028	2	1	4	BLQ	BLQ
0028	2	1	6	BLQ	BLQ
0028	2	1	8	BLQ	BLQ
0028	2	1	12	BLQ	BLQ
0028	2	1	16	BLQ	BLQ
0028	2	2	24	BLQ	BLQ
0028	2	2	32	BLQ	BLQ
0028	2	3	48	BLQ	BLQ
0029	2	1	0	BLQ	BLQ
0029	2	1	0.25	BLQ	BLQ
0029	2	1	0.50	BLQ	BLQ
0029	2	1	0.75	2.27	BLQ
0029	2	1	1	6.19	BLQ
0029	2	1	1.5	11.8	BLQ
0029	2	1	2	12.5	BLQ
0029	2	1	3	19.3	BLQ
0029	2	1	4	18.6	BLQ
0029	2	1	6	12.9	BLQ
0029	2	1	8	9.38	BLQ
0029	2	1	12	5.43	BLQ
0029	2	1	16	3.88	BLQ
0029	2	2	24	2.88	BLQ
0029	2	2	32	1.41	BLQ

Subject ID	Treatment ID	Study Day	Nominal Time (hr)	LB-102 Conc. (ng/mL)	LB-101 Conc. (ng/mL)
0029	2	3	48	BLQ	BLQ
0030	2	1	0	BLQ	BLQ
0030	2	1	0.25	BLQ	BLQ
0030	2	1	0.50	22.1	BLQ
0030	2	1	0.75	26.6	BLQ
0030	2	1	1	23.1	BLQ
0030	2	1	1.5	18.9	BLQ
0030	2	1	2	19.8	BLQ
0030	2	1	3	36.2	BLQ
0030	2	1	4	26.8	BLQ
0030	2	1	6	16.9	BLQ
0030	2	1	8	12.0	BLQ
0030	2	1	12	7.67	BLQ
0030	2	1	16	4.65	BLQ
0030	2	2	24	3.00	BLQ
0030	2	2	32	1.94	BLQ
0030	2	3	48	BLQ	BLQ
0032	2	1	0	BLQ	BLQ
0032	2	1	0.25	BLQ	BLQ
0032	2	1	0.50	4.79	BLQ
0032	2	1	0.75	13.1	BLQ
0032	2	1	1	24.6	BLQ
0032	2	1	1.5	30.7	BLQ
0032	2	1	2	34.4	BLQ
0032	2	1	3	39.0	BLQ
0032	2	1	4	30.8	BLQ
0032	2	1	6	21.8	BLQ
0032	2	1	8	15.2	BLQ
0032	2	1	12	8.52	BLQ
0032	2	1	16	4.50	BLQ
0032	2	2	24	2.20	BLQ
0032	2	2	32	1.39	BLQ
0032	2	3	48	BLQ	BLQ
0035	2	1	0	BLQ	BLQ
0035	2	1	0.25	BLQ	BLQ
0035	2	1	0.50	BLQ	BLQ
0035	2	1	0.75	2.61	BLQ
0035	2	1	1	5.40	BLQ
0035	2	1	1.5	9.19	BLQ
0035	2	1	2	12.0	BLQ

Subject ID	Treatment ID	Study Day	Nominal Time (hr)	LB-102 Conc. (ng/mL)	LB-101 Conc. (ng/mL)
0035	2	1	3	15.3	BLQ
0035	2	1	4	12.4	BLQ
0035	2	1	6	8.78	BLQ
0035	2	1	8	7.90	BLQ
0035	2	1	12	5.42	BLQ
0035	2	1	16	4.19	BLQ
0035	2	2	24	2.99	BLQ
0035	2	2	32	1.73	BLQ
0035	2	3	48	BLQ	BLQ
0037	2	1	0	BLQ	BLQ
0037	2	1	0.25	BLQ	BLQ
0037	2	1	0.50	BLQ	BLQ
0037	2	1	0.75	BLQ	BLQ
0037	2	1	1	BLQ	BLQ
0037	2	1	1.5	BLQ	BLQ
0037	2	1	2	BLQ	BLQ
0037	2	1	3	BLQ	BLQ
0037	2	1	4	BLQ	BLQ
0037	2	1	6	BLQ	BLQ
0037	2	1	8	BLQ	BLQ
0037	2	1	12	BLQ	BLQ
0037	2	1	16	BLQ	BLQ
0037	2	2	24	BLQ	BLQ
0037	2	2	32	BLQ	BLQ
0037	2	3	48	BLQ	BLQ
0042	2	1	0	BLQ	BLQ
0042	2	1	0.25	BLQ	BLQ
0042	2	1	0.50	BLQ	BLQ
0042	2	1	0.75	1.98	BLQ
0042	2	1	1	3.33	BLQ
0042	2	1	1.5	6.00	BLQ
0042	2	1	2	10.1	BLQ
0042	2	1	3	20.3	BLQ
0042	2	1	4	17.4	BLQ
0042	2	1	6	14.2	BLQ
0042	2	1	8	11.4	BLQ
0042	2	1	12	7.87	BLQ
0042	2	1	16	5.30	BLQ
0042	2	2	24	3.58	BLQ
0042	2	2	32	2.64	BLQ

Subject ID	Treatment ID	Study Day	Nominal Time (hr)	LB-102 Conc. (ng/mL)	LB-101 Conc. (ng/mL)
0042	2	3	48	1.56	BLQ
0049	2	1	0	BLQ	BLQ
0049	2	1	0.25	BLQ	BLQ
0049	2	1	0.50	1.16	BLQ
0049	2	1	0.75	5.59	BLQ
0049	2	1	1	7.13	BLQ
0049	2	1	1.5	6.76	BLQ
0049	2	1	2	7.56	BLQ
0049	2	1	3	14.5	BLQ
0049	2	1	4	10.5	BLQ
0049	2	1	6	8.39	BLQ
0049	2	1	8	6.64	BLQ
0049	2	1	12	3.94	BLQ
0049	2	1	16	2.60	BLQ
0049	2	2	24	1.87	BLQ
0049	2	2	32	1.32	BLQ
0049	2	3	48	BLQ	BLQ
0056	3	1	0	BLQ	BLQ
0056	3	1	0.25	1.59	BLQ
0056	3	1	0.50	101	BLQ
0056	3	1	0.75	262	3.94
0056	3	1	1	245	4.90
0056	3	1	1.5	282	6.29
0056	3	1	2	376	8.64
0056	3	1	3	323	7.46
0056	3	1	4	245	5.46
0056	3	1	6	168	4.21
0056	3	1	8	117	3.39
0056	3	1	12	67.6	2.59
0056	3	1	16	44.9	1.99
0056	3	2	24	24.7	1.32
0056	3	2	32	14.0	BLQ
0056	3	3	48	5.72	BLQ
0063	3	1	0	BLQ	BLQ
0063	3	1	0.25	BLQ	BLQ
0063	3	1	0.50	148	BLQ
0063	3	1	0.75	484	6.48
0063	3	1	1	525	10.1
0063	3	1	1.5	468	10.6
0063	3	1	2	384	8.89

Subject ID	Treatment ID	Study Day	Nominal Time (hr)	LB-102 Conc. (ng/mL)	LB-101 Conc. (ng/mL)
0063	3	1	3	372	9.79
0063	3	1	4	257	7.90
0063	3	1	6	162	5.57
0063	3	1	8	102	4.09
0063	3	1	12	55.2	2.71
0063	3	1	16	29.9	1.89
0063	3	2	24	14.7	BLQ
0063	3	2	32	9.07	BLQ
0063	3	3	48	3.71	BLQ
0064	3	1	0	BLQ	BLQ
0064	3	1	0.25	BLQ	BLQ
0064	3	1	0.50	74.5	BLQ
0064	3	1	0.75	174	2.73
0064	3	1	1	159	3.20
0064	3	1	1.5	233	4.85
0064	3	1	2	214	4.76
0064	3	1	3	292	5.28
0064	3	1	4	307	6.28
0064	3	1	6	175	4.44
0064	3	1	8	118	3.36
0064	3	1	12	71.4	2.45
0064	3	1	16	51.2	1.84
0064	3	2	24	29.8	1.26
0064	3	2	32	22.0	1.03
0064	3	3	48	13.3	BLQ
0068	3	1	0	BLQ	BLQ
0068	3	1	0.25	BLQ	BLQ
0068	3	1	0.50	BLQ	BLQ
0068	3	1	0.75	BLQ	BLQ
0068	3	1	1	BLQ	BLQ
0068	3	1	1.5	BLQ	BLQ
0068	3	1	2	BLQ	BLQ
0068	3	1	3	BLQ	BLQ
0068	3	1	4	BLQ	BLQ
0068	3	1	6	BLQ	BLQ
0068	3	1	8	BLQ	BLQ
0068	3	1	12	BLQ	BLQ
0068	3	1	16	BLQ	BLQ
0068	3	2	24	BLQ	BLQ
0068	3	2	32	BLQ	BLQ

Subject ID	Treatment ID	Study Day	Nominal Time (hr)	LB-102 Conc. (ng/mL)	LB-101 Conc. (ng/mL)
0068	3	3	48	BLQ	BLQ
0071	3	1	0	BLQ	BLQ
0071	3	1	0.25	BLQ	BLQ
0071	3	1	0.50	80.7	BLQ
0071	3	1	0.75	173	2.48
0071	3	1	1	247	3.85
0071	3	1	1.5	413	6.88
0071	3	1	2	490	9.04
0071	3	1	3	474	10.2
0071	3	1	4	300	6.49
0071	3	1	6	162	4.33
0071	3	1	8	102	2.68
0071	3	1	12	54.3	1.82
0071	3	1	16	33.2	1.38
0071	3	2	24	19.3	BLQ
0071	3	2	32	11.4	BLQ
0071	3	3	48	3.36	BLQ
0073	3	1	0	BLQ	BLQ
0073	3	1	0.25	BLQ	BLQ
0073	3	1	0.50	BLQ	BLQ
0073	3	1	0.75	BLQ	BLQ
0073	3	1	1	4.52	BLQ
0073	3	1	1.5	96.4	1.69
0073	3	1	2	112	2.85
0073	3	1	3	174	3.72
0073	3	1	4	203	4.23
0073	3	1	6	140	3.38
0073	3	1	8	109	2.99
0073	3	1	12	65.5	2.46
0073	3	1	16	43.4	1.94
0073	3	2	24	26.3	1.43
0073	3	2	32	19.1	BLQ
0073	3	3	48	9.93	BLQ
0074	3	1	0	BLQ	BLQ
0074	3	1	0.25	BLQ	BLQ
0074	3	1	0.50	5.03	BLQ
0074	3	1	0.75	17.9	BLQ
0074	3	1	1	17.5	BLQ
0074	3	1	1.5	19.5	BLQ
0074	3	1	2	16.7	BLQ

Subject ID	Treatment ID	Study Day	Nominal Time (hr)	LB-102 Conc. (ng/mL)	LB-101 Conc. (ng/mL)
0074	3	1	3	51.0	1.38
0074	3	1	4	188	5.94
0074	3	1	6	120	4.24
0074	3	1	8	89.4	3.33
0074	3	1	12	58.4	2.73
0074	3	1	16	42.3	2.05
0074	3	2	24	26.5	1.72
0074	3	2	32	18.3	1.06
0074	3	3	48	9.74	BLQ
0075	3	1	0	BLQ	BLQ
0075	3	1	0.25	BLQ	BLQ
0075	3	1	0.50	BLQ	BLQ
0075	3	1	0.75	BLQ	BLQ
0075	3	1	1	BLQ	BLQ
0075	3	1	1.5	BLQ	BLQ
0075	3	1	2	BLQ	BLQ
0075	3	1	3	BLQ	BLQ
0075	3	1	4	BLQ	BLQ
0075	3	1	6	BLQ	BLQ
0075	3	1	8	BLQ	BLQ
0075	3	1	12	BLQ	BLQ
0075	3	1	16	BLQ	BLQ
0075	3	2	24	BLQ	BLQ
0075	3	2	32	BLQ	BLQ
0075	3	3	48	BLQ	BLQ
0099	4	1	0	BLQ	BLQ
0099	4	1	0.25	BLQ	BLQ
0099	4	1	0.50	BLQ	BLQ
0099	4	1	0.75	BLQ	BLQ
0099	4	1	1	BLQ	BLQ
0099	4	1	1.5	BLQ	BLQ
0099	4	1	2	BLQ	BLQ
0099	4	1	3	BLQ	BLQ
0099	4	1	4	BLQ	BLQ
0099	4	1	6	BLQ	BLQ
0099	4	1	8	BLQ	BLQ
0099	4	1	12	BLQ	BLQ
0099	4	1	16	BLQ	BLQ
0099	4	2	24	BLQ	BLQ
0099	4	2	32	BLQ	BLQ

Subject ID	Treatment ID	Study Day	Nominal Time (hr)	LB-102 Conc. (ng/mL)	LB-101 Conc. (ng/mL)
0099	4	3	48	BLQ	BLQ
0100	4	1	0	BLQ	BLQ
0100	4	1	0.25	BLQ	BLQ
0100	4	1	0.50	BLQ	BLQ
0100	4	1	0.75	BLQ	BLQ
0100	4	1	1	BLQ	BLQ
0100	4	1	1.5	BLQ	BLQ
0100	4	1	2	BLQ	BLQ
0100	4	1	3	BLQ	BLQ
0100	4	1	4	BLQ	BLQ
0100	4	1	6	BLQ	BLQ
0100	4	1	8	BLQ	BLQ
0100	4	1	12	BLQ	BLQ
0100	4	1	16	BLQ	BLQ
0100	4	2	24	BLQ	BLQ
0100	4	2	32	BLQ	BLQ
0100	4	3	48	BLQ	BLQ
0103	4	1	0	BLQ	BLQ
0103	4	1	0.25	BLQ	BLQ
0103	4	1	0.50	32.7	BLQ
0103	4	1	0.75	267	4.78
0103	4	1	1	702	15.2
0103	4	1	1.5	816	24.1
0103	4	1	2	641	19.8
0103	4	1	3	856	24.6
0103	4	1	4	577	18.9
0103	4	1	6	345	13.4
0103	4	1	8	231	10.9
0103	4	1	12	109	6.02
0103	4	1	16	76.0	4.82
0103	4	2	24	48.7	2.93
0103	4	2	32	25.7	1.64
0103	4	3	48	8.07	BLQ
0104	4	1	0	BLQ	BLQ
0104	4	1	0.25	2.30	BLQ
0104	4	1	0.50	350	3.41
0104	4	1	0.75	688	17.2
0104	4	1	1	636	17.2
0104	4	1	1.5	569	16.4
0104	4	1	2	738	20.2

Subject ID	Treatment ID	Study Day	Nominal Time (hr)	LB-102 Conc. (ng/mL)	LB-101 Conc. (ng/mL)
0104	4	1	3	737	21.9
0104	4	1	4	520	15.8
0104	4	1	6	351	12.3
0104	4	1	8	243	9.51
0104	4	1	12	152	6.95
0104	4	1	16	104	4.86
0104	4	2	24	66.5	3.49
0104	4	2	32	41.8	2.28
0104	4	3	48	19.9	1.25
0109	4	1	0	BLQ	BLQ
0109	4	1	0.25	BLQ	BLQ
0109	4	1	0.50	46.3	BLQ
0109	4	1	0.75	241	1.37
0109	4	1	1	573	3.62
0109	4	1	1.5	899	8.48
0109	4	1	2	637	6.32
0109	4	1	3	794	7.41
0109	4	1	4	605	5.96
0109	4	1	6	419	4.48
0109	4	1	8	289	3.62
0109	4	1	12	172	2.62
0109	4	1	16	108	1.84
0109	4	2	24	62.2	1.36
0109	4	2	32	43.6	BLQ
0109	4	3	48	19.1	BLQ
0116	4	1	0	BLQ	BLQ
0116	4	1	0.25	4.51	BLQ
0116	4	1	0.50	623	11.1
0116	4	1	0.75	605	37.2
0116	4	1	1	650	34.8
0116	4	1	1.5	1300	65.1
0116	4	1	2	1200	59.9
0116	4	1	3	878	48.3
0116	4	1	4	615	37.4
0116	4	1	6	356	24.0
0116	4	1	8	203	13.8
0116	4	1	12	95.1	7.41
0116	4	1	16	55.6	4.98
0116	4	2	24	43.3	3.60
0116	4	2	32	33.9	2.38

Subject ID	Treatment ID	Study Day	Nominal Time (hr)	LB-102 Conc. (ng/mL)	LB-101 Conc. (ng/mL)
0116	4	3	48	16.9	1.59
0119	4	1	0	BLQ	BLQ
0119	4	1	0.25	14.4	BLQ
0119	4	1	0.50	508	4.14
0119	4	1	0.75	790	12.4
0119	4	1	1	675	15.3
0119	4	1	1.5	1290	24.2
0119	4	1	2	1060	24.6
0119	4	1	3	984	23.8
0119	4	1	4	749	20.3
0119	4	1	6	483	15.5
0119	4	1	8	304	11.2
0119	4	1	16	105	6.64
0119	4	2	24	61.7	4.61
0119	4	2	32	29.0	2.36
0119	4	3	48	9.04	BLQ
0120	4	1	0	BLQ	BLQ
0120	4	1	0.25	22.3	BLQ
0120	4	1	0.50	545	9.80
0120	4	1	0.75	478	13.1
0120	4	1	1	491	13.1
0120	4	1	1.5	687	17.4
0120	4	1	2	766	21.8
0120	4	1	3	771	21.8
0120	4	1	4	554	17.0
0120	4	1	6	313	12.1
0120	4	1	8	198	8.62
0120	4	1	12	109	5.64
0120	4	1	16	69.0	4.24
0120	4	2	24	51.4	2.88
0120	4	2	32	34.4	1.87
0120	4	3	48	15.6	1.05
0154	5	1	0	BLQ	BLQ
0154	5	1	0.25	BLQ	BLQ
0154	5	1	0.50	BLQ	BLQ
0154	5	1	0.75	BLQ	BLQ
0154	5	1	1	BLQ	BLQ
0154	5	1	1.5	BLQ	BLQ
0154	5	1	2	BLQ	BLQ
0154	5	1	3	BLQ	BLQ

Subject ID	Treatment ID	Study Day	Nominal Time (hr)	LB-102 Conc. (ng/mL)	LB-101 Conc. (ng/mL)
0154	5	1	4	BLQ	BLQ
0154	5	1	6	BLQ	BLQ
0154	5	1	8	BLQ	BLQ
0154	5	1	12	BLQ	BLQ
0154	5	1	16	BLQ	BLQ
0154	5	2	24	BLQ	BLQ
0154	5	2	32	BLQ	BLQ
0154	5	3	48	BLQ	BLQ
0154	5	8	0	BLQ	BLQ
0154	5	15	0	BLQ	BLQ
0156	5	1	0	BLQ	BLQ
0156	5	1	0.25	4.66	BLQ
0156	5	1	0.50	158	2.60
0156	5	1	0.75	332	7.01
0156	5	1	1	445	13.0
0156	5	1	1.5	384	12.5
0156	5	1	2	464	12.3
0156	5	1	3	566	16.3
0156	5	1	4	439	13.0
0156	5	1	6	244	8.59
0156	5	1	8	168	6.49
0156	5	1	12	77.2	3.79
0156	5	1	16	33.6	1.89
0156	5	2	24	17.9	1.18
0156	5	2	32	10.9	BLQ
0156	5	3	48	5.27	BLQ
0156	5	8	0	BLQ	BLQ
0156	5	15	0	BLQ	BLQ
0157	5	1	0	BLQ	BLQ
0157	5	1	0.25	BLQ	BLQ
0157	5	1	0.50	70.3	BLQ
0157	5	1	0.75	226	5.50
0157	5	1	1	217	8.06
0157	5	1	1.5	265	9.18
0157	5	1	2	348	11.0
0157	5	1	3	526	14.8
0157	5	1	4	739	23.7
0157	5	1	6	477	17.5
0157	5	1	8	304	12.1
0157	5	1	12	138	7.03

Subject ID	Treatment ID	Study Day	Nominal Time (hr)	LB-102 Conc. (ng/mL)	LB-101 Conc. (ng/mL)
0157	5	1	16	76.6	4.67
0157	5	2	24	41.6	2.73
0157	5	2	32	24.9	1.39
0157	5	3	48	9.84	BLQ
0157	5	8	0	BLQ	BLQ
0157	5	15	0	BLQ	BLQ
0160	5	1	0	BLQ	BLQ
0160	5	1	0.25	7.14	BLQ
0160	5	1	0.50	250	1.29
0160	5	1	0.75	179	2.75
0160	5	1	1	119	2.09
0160	5	1	1.5	261	3.33
0160	5	1	2	539	9.72
0160	5	1	3	653	11.7
0160	5	1	4	502	10.8
0160	5	1	6	307	7.47
0160	5	1	8	213	5.82
0160	5	1	12	130	4.55
0160	5	1	16	80.9	3.21
0160	5	2	24	38.9	1.93
0160	5	2	32	20.3	1.17
0160	5	3	48	7.25	BLQ
0160	5	8	0	BLQ	BLQ
0160	5	15	0	BLQ	BLQ
0162	5	1	0	BLQ	BLQ
0162	5	1	0.25	BLQ	BLQ
0162	5	1	0.50	59.0	BLQ
0162	5	1	0.75	125	2.31
0162	5	1	1	74.4	2.11
0162	5	1	1.5	142	2.90
0162	5	1	2	397	9.50
0162	5	1	3	555	11.0
0162	5	1	4	413	8.80
0162	5	1	6	299	7.36
0162	5	1	8	211	6.39
0162	5	1	12	124	4.40
0162	5	1	16	74.4	3.13
0162	5	2	24	40.9	2.07
0162	5	2	32	26.5	1.30
0162	5	3	48	11.1	BLQ

Subject ID	Treatment ID	Study Day	Nominal Time (hr)	LB-102 Conc. (ng/mL)	LB-101 Conc. (ng/mL)
0162	5	8	0	BLQ	BLQ
0162	5	15	0	BLQ	BLQ
0165	5	1	0	BLQ	BLQ
0165	5	1	0.25	BLQ	BLQ
0165	5	1	0.50	1.02	BLQ
0165	5	1	0.75	47.2	1.26
0165	5	1	1	310	14.0
0165	5	1	1.5	493	21.5
0165	5	1	2	584	30.6
0165	5	1	3	665	28.2
0165	5	1	4	505	24.2
0165	5	1	6	331	19.9
0165	5	1	8	203	14.0
0165	5	1	12	97.8	8.13
0165	5	1	16	50.4	4.67
0165	5	2	24	24.5	2.60
0165	5	2	32	18.3	1.11
0165	5	3	48	8.21	BLQ
0165	5	8	0	BLQ	BLQ
0165	5	15	0	BLQ	BLQ
0168	5	1	0	BLQ	BLQ
0168	5	1	0.25	4.77	BLQ
0168	5	1	0.50	230	2.49
0168	5	1	0.75	392	8.34
0168	5	1	1	315	8.44
0168	5	1	1.5	317	9.55
0168	5	1	2	293	8.59
0168	5	1	3	401	10.4
0168	5	1	4	308	9.92
0168	5	1	6	212	7.37
0168	5	1	8	153	4.94
0168	5	1	12	87.3	3.74
0168	5	1	16	56.3	2.79
0168	5	2	24	30.9	1.81
0168	5	2	32	BLQ	BLQ
0168	5	3	48	9.17	BLQ
0168	5	8	0	BLQ	BLQ
0168	5	15	0	BLQ	BLQ
0169	5	1	0	BLQ	BLQ
0169	5	1	0.25	BLQ	BLQ

Subject ID	Treatment ID	Study Day	Nominal Time (hr)	LB-102 Conc. (ng/mL)	LB-101 Conc. (ng/mL)
0169	5	1	0.50	BLQ	BLQ
0169	5	1	0.75	BLQ	BLQ
0169	5	1	1	BLQ	BLQ
0169	5	1	1.5	BLQ	BLQ
0169	5	1	2	BLQ	BLQ
0169	5	1	3	BLQ	BLQ
0169	5	1	4	BLQ	BLQ
0169	5	1	6	BLQ	BLQ
0169	5	1	8	BLQ	BLQ
0169	5	1	12	BLQ	BLQ
0169	5	1	16	BLQ	BLQ
0169	5	2	24	BLQ	BLQ
0169	5	2	32	16.2	1.69
0169	5	3	48	BLQ	BLQ
0169	5	8	0	BLQ	BLQ
0169	5	15	0	BLQ	BLQ
2032	6	1	0	BLQ	BLQ
2032	6	1	0.25	1.40	BLQ
2032	6	1	0.50	29.8	BLQ
2032	6	1	0.75	51.4	1.02
2032	6	1	1	73.5	1.55
2032	6	1	1.5	144	3.90
2032	6	1	2	142	4.19
2032	6	1	3	143	4.21
2032	6	1	4	115	3.43
2032	6	1	6	80.3	2.90
2032	6	1	8	56.2	2.01
2032	6	1	12	26.5	1.25
2032	6	1	16	89.5	2.64
2032	6	2	0	33.6	1.86
2032	6	3	0	47.3	2.42
2032	6	4	0	49.3	2.50
2032	6	5	0	46.7	2.18
2032	6	6	0	52.9	2.78
2032	6	7	0	67.9	3.53
2032	6	7	0.25	62.7	3.40
2032	6	7	0.50	78.8	3.49
2032	6	7	0.75	102	4.17
2032	6	7	1	114	4.75
2032	6	7	1.5	143	5.61

Subject ID	Treatment ID	Study Day	Nominal Time (hr)	LB-102 Conc. (ng/mL)	LB-101 Conc. (ng/mL)
2032	6	7	2	197	7.38
2032	6	7	3	220	7.71
2032	6	7	4	172	6.13
2032	6	7	6	121	4.59
2032	6	7	8	96.5	3.52
2032	6	7	12	56.6	2.68
2032	6	7	16	32.6	1.70
2032	6	8	24	17.5	1.12
2032	6	8	32	12.2	BLQ
2032	6	9	48	7.10	BLQ
2034	6	1	0	BLQ	BLQ
2034	6	1	0.25	BLQ	BLQ
2034	6	1	0.50	BLQ	BLQ
2034	6	1	0.75	8.68	BLQ
2034	6	1	1	29.3	BLQ
2034	6	1	1.5	47.4	1.45
2034	6	1	2	46.5	1.55
2034	6	1	3	95.8	2.28
2034	6	1	4	87.3	2.13
2034	6	1	6	67.8	2.06
2034	6	1	8	55.2	1.56
2034	6	1	12	37.7	1.29
2034	6	1	16	103	3.02
2034	6	2	0	57.9	2.29
2034	6	3	0	98.8	4.05
2034	6	4	0	90.5	3.92
2034	6	5	0	89.9	3.99
2034	6	6	0	87.8	4.11
2034	6	7	0	77.8	3.90
2034	6	7	0.25	77.9	3.82
2034	6	7	0.50	79.6	3.77
2034	6	7	0.75	78.6	3.91
2034	6	7	1	136	4.67
2034	6	7	1.5	145	5.93
2034	6	7	2	135	5.41
2034	6	7	3	187	6.67
2034	6	7	4	180	5.96
2034	6	7	6	161	5.95
2034	6	7	8	127	5.36
2034	6	7	12	79.8	3.65

Subject ID	Treatment ID	Study Day	Nominal Time (hr)	LB-102 Conc. (ng/mL)	LB-101 Conc. (ng/mL)
2034	6	7	16	51.2	2.44
2034	6	8	24	33.3	1.73
2034	6	8	32	19.1	1.11
2034	6	9	48	6.02	BLQ
2042	6	1	0	BLQ	BLQ
2042	6	1	0.25	BLQ	BLQ
2042	6	1	0.50	BLQ	BLQ
2042	6	1	0.75	BLQ	BLQ
2042	6	1	1	BLQ	BLQ
2042	6	1	1.5	BLQ	BLQ
2042	6	1	2	BLQ	BLQ
2042	6	1	3	BLQ	BLQ
2042	6	1	4	BLQ	BLQ
2042	6	1	6	BLQ	BLQ
2042	6	1	8	BLQ	BLQ
2042	6	1	12	BLQ	BLQ
2042	6	1	16	BLQ	BLQ
2042	6	2	0	BLQ	BLQ
2042	6	3	0	BLQ	BLQ
2042	6	4	0	BLQ	BLQ
2042	6	5	0	BLQ	BLQ
2042	6	6	0	BLQ	BLQ
2042	6	7	0	BLQ	BLQ
2042	6	7	0.25	BLQ	BLQ
2042	6	7	0.50	BLQ	BLQ
2042	6	7	0.75	BLQ	BLQ
2042	6	7	1	BLQ	BLQ
2042	6	7	1.5	BLQ	BLQ
2042	6	7	2	BLQ	BLQ
2042	6	7	3	BLQ	BLQ
2042	6	7	4	BLQ	BLQ
2042	6	7	6	BLQ	BLQ
2042	6	7	8	BLQ	BLQ
2042	6	7	12	BLQ	BLQ
2042	6	7	16	BLQ	BLQ
2042	6	8	24	BLQ	BLQ
2042	6	8	32	BLQ	BLQ
2042	6	9	48	BLQ	BLQ
2045	6	1	0	BLQ	BLQ
2045	6	1	0.25	BLQ	BLQ

Subject ID	Treatment ID	Study Day	Nominal Time (hr)	LB-102 Conc. (ng/mL)	LB-101 Conc. (ng/mL)
2045	6	1	0.50	9.46	BLQ
2045	6	1	0.75	67.1	1.12
2045	6	1	1	109	3.12
2045	6	1	1.5	98.6	3.62
2045	6	1	2	96.7	3.49
2045	6	1	3	104	3.42
2045	6	1	4	73.0	2.63
2045	6	1	6	52.3	2.04
2045	6	1	8	41.7	1.64
2045	6	1	12	26.2	1.28
2045	6	1	16	75.6	2.62
2045	6	2	0	40.0	1.89
2045	6	3	0	64.3	2.87
2045	6	4	0	71.9	3.16
2045	6	5	0	72.1	3.08
2045	6	6	0	60.6	2.63
2045	6	7	0	68.9	3.43
2045	6	7	0.25	80.0	3.56
2045	6	7	0.50	127	4.08
2045	6	7	0.75	142	4.89
2045	6	7	1	160	5.13
2045	6	7	1.5	185	6.09
2045	6	7	2	214	6.39
2045	6	7	3	189	6.00
2045	6	7	4	162	5.58
2045	6	7	6	115	4.52
2045	6	7	8	94.1	4.04
2045	6	7	12	63.5	3.08
2045	6	7	16	48.2	2.66
2045	6	8	24	29.2	1.83
2045	6	8	32	19.0	1.38
2045	6	9	48	9.06	BLQ
2047	6	1	0	BLQ	BLQ
2047	6	1	0.25	BLQ	BLQ
2047	6	1	0.50	BLQ	BLQ
2047	6	1	0.75	BLQ	BLQ
2047	6	1	1	BLQ	BLQ
2047	6	1	1.5	BLQ	BLQ
2047	6	1	2	BLQ	BLQ
2047	6	1	3	BLQ	BLQ

Subject ID	Treatment ID	Study Day	Nominal Time (hr)	LB-102 Conc. (ng/mL)	LB-101 Conc. (ng/mL)
2047	6	1	4	BLQ	BLQ
2047	6	1	6	BLQ	BLQ
2047	6	1	8	BLQ	BLQ
2047	6	1	12	BLQ	BLQ
2047	6	1	16	BLQ	BLQ
2047	6	2	0	BLQ	BLQ
2047	6	3	0	BLQ	BLQ
2047	6	4	0	BLQ	BLQ
2047	6	5	0	BLQ	BLQ
2047	6	6	0	BLQ	BLQ
2047	6	7	0	BLQ	BLQ
2047	6	7	0.25	BLQ	BLQ
2047	6	7	0.50	BLQ	BLQ
2047	6	7	0.75	BLQ	BLQ
2047	6	7	1	BLQ	BLQ
2047	6	7	1.5	BLQ	BLQ
2047	6	7	2	BLQ	BLQ
2047	6	7	3	BLQ	BLQ
2047	6	7	4	BLQ	BLQ
2047	6	7	6	BLQ	BLQ
2047	6	7	8	BLQ	BLQ
2047	6	7	12	BLQ	BLQ
2047	6	7	16	BLQ	BLQ
2047	6	8	24	BLQ	BLQ
2047	6	8	32	BLQ	BLQ
2047	6	9	48	BLQ	BLQ
2050	6	1	0	BLQ	BLQ
2050	6	1	0.25	2.89	BLQ
2050	6	1	0.50	55.0	1.20
2050	6	1	0.75	49.8	1.87
2050	6	1	1	48.4	2.05
2050	6	1	1.5	73.2	2.41
2050	6	1	2	126	4.90
2050	6	1	3	130	4.80
2050	6	1	4	110	5.17
2050	6	1	6	77.1	3.86
2050	6	1	8	56.2	3.10
2050	6	1	12	28.1	2.02
2050	6	1	16	92.6	4.10
2050	6	2	0	47.4	2.85

Subject ID	Treatment ID	Study Day	Nominal Time (hr)	LB-102 Conc. (ng/mL)	LB-101 Conc. (ng/mL)
2050	6	3	0	58.7	4.15
2050	6	4	0	65.5	4.56
2050	6	5	0	74.5	4.79
2050	6	6	0	79.0	5.16
2050	6	7	0	79.3	5.50
2050	6	7	0.25	131	5.74
2050	6	7	0.50	126	6.83
2050	6	7	0.75	119	6.66
2050	6	7	1	140	7.25
2050	6	7	1.5	177	8.82
2050	6	7	2	261	11.5
2050	6	7	3	231	10.6
2050	6	7	4	193	9.99
2050	6	7	6	127	7.16
2050	6	7	8	103	6.28
2050	6	7	12	67.3	4.68
2050	6	7	16	50.9	3.90
2050	6	8	24	33.2	2.76
2050	6	8	32	18.3	1.75
2050	6	9	48	9.27	BLQ
2053	6	1	0	BLQ	BLQ
2053	6	1	0.25	BLQ	BLQ
2053	6	1	0.50	11.3	BLQ
2053	6	1	0.75	12.1	BLQ
2053	6	1	1	26.6	BLQ
2053	6	1	1.5	67.0	2.40
2053	6	1	2	98.3	4.04
2053	6	1	3	117	4.39
2053	6	1	4	102	3.89
2053	6	1	6	72.6	3.34
2053	6	1	8	45.6	2.07
2053	6	1	12	26.6	1.55
2053	6	1	16	82.3	3.39
2053	6	2	0	40.0	2.37
2053	6	3	0	53.9	3.19
2053	6	4	0	50.0	2.75
2053	6	5	0	59.9	3.01
2053	6	6	0	64.0	3.60
2053	6	7	0	63.2	3.75
2053	6	7	0.25	65.3	3.75

Subject ID	Treatment ID	Study Day	Nominal Time (hr)	LB-102 Conc. (ng/mL)	LB-101 Conc. (ng/mL)
2053	6	7	0.50	70.4	3.58
2053	6	7	0.75	94.7	3.86
2053	6	7	1	91.9	4.28
2053	6	7	1.5	109	5.06
2053	6	7	2	124	5.25
2053	6	7	3	181	6.86
2053	6	7	4	152	6.05
2053	6	7	6	122	5.18
2053	6	7	8	91.2	4.50
2053	6	7	12	57.0	2.92
2053	6	7	16	34.1	1.85
2053	6	8	24	19.3	1.34
2053	6	8	32	10.8	BLQ
2053	6	9	48	4.25	BLQ
2055	6	1	0	BLQ	BLQ
2055	6	1	0.25	BLQ	BLQ
2055	6	1	0.50	31.1	BLQ
2055	6	1	0.75	136	3.47
2055	6	1	1	133	5.13
2055	6	1	1.5	132	5.77
2055	6	1	2	157	6.67
2055	6	1	3	137	5.55
2055	6	1	4	118	4.58
2055	6	1	6	69.9	3.25
2055	6	1	8	49.4	2.38
2055	6	1	12	28.6	1.65
2055	6	1	16	122	4.23
2055	6	2	0	49.0	2.43
2055	6	3	0	63.9	3.72
2055	6	4	0	79.3	4.59
2055	6	5	0	66.0	4.09
2055	6	6	0	81.4	5.19
2055	6	7	0	59.2	4.12
2055	6	7	0.25	63.0	3.89
2055	6	7	0.50	85.6	4.21
2055	6	7	0.75	187	6.11
2055	6	7	1	281	8.85
2055	6	7	1.5	261	11.9
2055	6	7	2	255	11.4
2055	6	7	3	195	8.24

Subject ID	Treatment ID	Study Day	Nominal Time (hr)	LB-102 Conc. (ng/mL)	LB-101 Conc. (ng/mL)
2055	6	7	4	148	6.36
2055	6	7	6	109	5.47
2055	6	7	8	84.3	4.61
2055	6	7	12	50.1	3.09
2055	6	7	16	34.5	2.10
2055	6	8	24	27.0	1.93
2055	6	8	32	20.4	1.38
2055	6	9	48	11.1	BLQ
2059	7	1	0	BLQ	BLQ
2059	7	1	0.25	BLQ	BLQ
2059	7	1	0.50	20.3	BLQ
2059	7	1	0.75	129	3.88
2059	7	1	1	92.0	5.24
2059	7	1	1.5	107	5.41
2059	7	1	2	361	12.3
2059	7	1	3	314	15.6
2059	7	1	4	289	14.0
2059	7	1	6	160	8.93
2059	7	1	8	104	5.86
2059	7	1	12	53.2	3.49
2059	7	1	16	202	10.5
2059	7	2	0	92.6	5.57
2059	7	3	0	135	8.11
2059	7	4	0	46.7	3.94
2059	7	5	0	7.00	BLQ
2065	7	1	0	BLQ	BLQ
2065	7	1	0.25	BLQ	BLQ
2065	7	1	0.50	BLQ	BLQ
2065	7	1	0.75	BLQ	BLQ
2065	7	1	1	BLQ	BLQ
2065	7	1	1.5	BLQ	BLQ
2065	7	1	2	BLQ	BLQ
2065	7	1	3	BLQ	BLQ
2065	7	1	4	BLQ	BLQ
2065	7	1	6	BLQ	BLQ
2065	7	1	8	BLQ	BLQ
2065	7	1	12	BLQ	BLQ
2065	7	1	16	BLQ	BLQ
2065	7	2	0	BLQ	BLQ
2065	7	3	0	BLQ	BLQ

Subject ID	Treatment ID	Study Day	Nominal Time (hr)	LB-102 Conc. (ng/mL)	LB-101 Conc. (ng/mL)
2065	7	4	0	BLQ	BLQ
2065	7	5	0	BLQ	BLQ
2066	7	1	0	BLQ	BLQ
2066	7	1	0.25	BLQ	BLQ
2066	7	1	0.50	76.1	BLQ
2066	7	1	0.75	171	4.96
2066	7	1	1	119	5.20
2066	7	1	1.5	150	6.66
2066	7	1	2	179	7.62
2066	7	1	3	214	8.44
2066	7	1	4	203	8.03
2066	7	1	6	133	5.91
2066	7	1	8	92.8	4.72
2066	7	1	12	51.1	2.80
2066	7	1	16	112	4.60
2066	7	2	0	108	5.85
2066	7	3	0	88.8	6.28
2066	7	4	0	37.7	3.15
2066	7	5	0	6.76	BLQ
2069	7	1	0	BLQ	BLQ
2069	7	1	0.25	BLQ	BLQ
2069	7	1	0.50	BLQ	BLQ
2069	7	1	0.75	2.44	BLQ
2069	7	1	1	6.87	BLQ
2069	7	1	1.5	113	1.88
2069	7	1	2	182	4.18
2069	7	1	3	377	7.92
2069	7	1	4	291	6.78
2069	7	1	6	182	5.03
2069	7	1	8	117	3.56
2069	7	1	12	50.7	1.99
2069	7	1	16	110	3.13
2069	7	2	0	119	4.11
2069	7	3	0	43.4	2.08
2074	7	1	0	BLQ	BLQ
2074	7	1	0.25	BLQ	BLQ
2074	7	1	0.50	BLQ	BLQ
2074	7	1	0.75	BLQ	BLQ
2074	7	1	1	BLQ	BLQ
2074	7	1	1.5	BLQ	BLQ

Subject ID	Treatment ID	Study Day	Nominal Time (hr)	LB-102 Conc. (ng/mL)	LB-101 Conc. (ng/mL)
2074	7	1	2	BLQ	BLQ
2074	7	1	3	BLQ	BLQ
2074	7	1	4	BLQ	BLQ
2074	7	1	6	BLQ	BLQ
2074	7	1	8	BLQ	BLQ
2074	7	1	12	BLQ	BLQ
2074	7	1	16	BLQ	BLQ
2074	7	2	0	BLQ	BLQ
2074	7	3	0	BLQ	BLQ
2074	7	4	0	BLQ	BLQ
2074	7	5	0	BLQ	BLQ
2076	7	1	0	BLQ	BLQ
2076	7	1	0.25	34.9	BLQ
2076	7	1	0.50	317	7.88
2076	7	1	0.75	209	8.26
2076	7	1	1	158	6.40
2076	7	1	1.5	169	6.34
2076	7	1	2	166	6.45
2076	7	1	3	251	9.68
2076	7	1	4	186	6.60
2076	7	1	6	132	5.23
2076	7	1	8	83.9	3.58
2076	7	1	12	53.9	2.87
2076	7	1	16	176	6.61
2076	7	2	0	73.6	4.07
2076	7	3	0	135	7.52
2078	7	1	0	BLQ	BLQ
2078	7	1	0.25	BLQ	BLQ
2078	7	1	0.50	78.6	BLQ
2078	7	1	0.75	106	1.79
2078	7	1	1	116	2.89
2078	7	1	1.5	153	3.96
2078	7	1	2	286	6.89
2078	7	1	3	285	6.20
2078	7	1	4	216	5.08
2078	7	1	6	139	4.06
2078	7	1	8	104	3.13
2078	7	1	12	62.1	2.10
2078	7	1	16	179	4.93
2078	7	2	0	108	4.02

Subject ID	Treatment ID	Study Day	Nominal Time (hr)	LB-102 Conc. (ng/mL)	LB-101 Conc. (ng/mL)
2078	7	3	0	152	5.44
2078	7	4	0	87.1	4.24
2078	7	5	0	40.0	2.12
2079	7	1	0	BLQ	BLQ
2079	7	1	0.25	BLQ	BLQ
2079	7	1	0.50	33.3	BLQ
2079	7	1	0.75	48.0	BLQ
2079	7	1	1	281	3.79
2079	7	1	1.5	266	4.40
2079	7	1	2	371	6.64
2079	7	1	3	396	8.46
2079	7	1	4	279	6.61
2079	7	1	6	202	5.00
2079	7	1	8	170	4.23
2079	7	1	12	82.3	3.36
2079	7	1	16	281	8.10
2079	7	2	0	136	5.83
2079	7	3	0	172	8.06
2080	8	1	0	BLQ	BLQ
2080	8	1	0.25	3.35	BLQ
2080	8	1	0.50	138	1.84
2080	8	1	0.75	264	5.85
2080	8	1	1	263	8.83
2080	8	1	1.5	289	9.44
2080	8	1	2	278	9.37
2080	8	1	3	314	9.43
2080	8	1	4	270	8.86
2080	8	1	6	160	6.45
2080	8	1	8	98.8	4.61
2080	8	1	12	53.2	2.66
2080	8	1	16	289	11.1
2080	8	2	24*	96.5	5.98
2080	8	4	0	181	10.5
2080	8	3	48*	164	9.98
2080	8	5	0	172	11.2
2080	8	6	0	152	10.4
2080	8	6	0.25	139	10.1
2080	8	6	0.50	230	11.8
2080	8	6	1	458	19.7
2080	8	6	2	511	19.2

Subject ID	Treatment ID	Study Day	Nominal Time (hr)	LB-102 Conc. (ng/mL)	LB-101 Conc. (ng/mL)
2080	8	6	4	331	16.6
2080	8	6	8	199	12.0
2080	8	6	12	129	8.55
2080	8	6	12.25	128	7.73
2080	8	6	12.5	134	8.18
2080	8	6	13	385	13.4
2080	8	6	14	568	21.7
2080	8	6	16	379	18.6
2080	8	6	18	273	14.7
2080	8	6	20	230	13.4
2080	8	7	0	154	9.94
2080	8	8	24	62.0	4.66
2080	8	8	32	38.2	2.74
2080	8	9	48	21.4	1.90
2082	8	1	0	BLQ	BLQ
2082	8	1	0.25	BLQ	BLQ
2082	8	1	0.50	BLQ	BLQ
2082	8	1	0.75	BLQ	BLQ
2082	8	1	1	BLQ	BLQ
2082	8	1	1.5	BLQ	BLQ
2082	8	1	2	BLQ	BLQ
2082	8	1	3	BLQ	BLQ
2082	8	1	4	BLQ	BLQ
2082	8	1	6	BLQ	BLQ
2082	8	1	8	BLQ	BLQ
2082	8	1	12	BLQ	BLQ
2082	8	1	16	BLQ	BLQ
2082	8	2	24*	BLQ	BLQ
2082	8	4	0	BLQ	BLQ
2082	8	3	48*	BLQ	BLQ
2082	8	5	0	BLQ	BLQ
2082	8	6	0	BLQ	BLQ
2082	8	6	0.25	BLQ	BLQ
2082	8	6	0.50	BLQ	BLQ
2082	8	6	1	BLQ	BLQ
2082	8	6	2	BLQ	BLQ
2082	8	6	4	BLQ	BLQ
2082	8	6	8	BLQ	BLQ
2082	8	6	12	BLQ	BLQ
2082	8	6	12.25	BLQ	BLQ

Subject ID	Treatment ID	Study Day	Nominal Time (hr)	LB-102 Conc. (ng/mL)	LB-101 Conc. (ng/mL)
2082	8	6	12.5	BLQ	BLQ
2082	8	6	13	BLQ	BLQ
2082	8	6	14	BLQ	BLQ
2082	8	6	16	BLQ	BLQ
2082	8	6	18	BLQ	BLQ
2082	8	6	20	BLQ	BLQ
2082	8	7	0	BLQ	BLQ
2082	8	8	24	BLQ	BLQ
2082	8	8	32	BLQ	BLQ
2082	8	9	48	BLQ	BLQ
2087	8	1	0	BLQ	BLQ
2087	8	1	0.25	BLQ	BLQ
2087	8	1	0.50	BLQ	BLQ
2087	8	1	0.75	8.86	BLQ
2087	8	1	1	50.6	1.43
2087	8	1	1.5	35.5	1.38
2087	8	1	2	232	4.38
2087	8	1	3	234	6.05
2087	8	1	4	200	5.20
2087	8	1	6	144	4.49
2087	8	1	8	93.9	3.02
2087	8	1	12	48.3	2.22
2087	8	1	16	191	5.38
2087	8	2	24*	48.8	2.54
2087	8	4	0	93.3	4.89
2087	8	3	48*	85.2	4.53
2087	8	5	0	80.2	4.34
2087	8	6	0	89.6	4.63
2087	8	6	0.25	86.0	4.67
2087	8	6	0.50	87.2	4.57
2087	8	6	1	156	6.22
2087	8	6	2	217	7.15
2087	8	6	4	249	8.20
2087	8	6	8	120	4.63
2087	8	6	12	72.9	3.65
2087	8	6	12.25	68.3	3.32
2087	8	6	12.5	83.2	3.74
2087	8	6	13	126	4.76
2087	8	6	14	191	5.95
2087	8	6	16	201	6.53

Subject ID	Treatment ID	Study Day	Nominal Time (hr)	LB-102 Conc. (ng/mL)	LB-101 Conc. (ng/mL)
2087	8	6	18	150	5.71
2087	8	6	20	115	4.80
2087	8	7	0	83.7	4.02
2087	8	8	24	31.9	2.24
2087	8	8	32	19.4	1.22
2087	8	9	48	6.30	BLQ
2092	8	1	0	BLQ	BLQ
2092	8	1	0.25	BLQ	BLQ
2092	8	1	0.50	70.7	1.09
2092	8	1	0.75	117	2.82
2092	8	1	1	148	3.63
2092	8	1	1.5	168	4.57
2092	8	1	2	221	6.57
2092	8	1	3	225	7.50
2092	8	1	4	178	5.89
2092	8	1	6	111	4.20
2092	8	1	8	73.3	3.34
2092	8	1	12	41.2	2.27
2092	8	1	16	173	5.54
2092	8	2	24*	84.5	4.30
2092	8	4	0	51.0	3.49
2092	8	3	48*	87.5	5.19
2093	8	1	0	BLQ	BLQ
2093	8	1	0.25	BLQ	BLQ
2093	8	1	0.50	14.8	BLQ
2093	8	1	0.75	107	1.85
2093	8	1	1	153	4.24
2093	8	1	1.5	193	5.55
2093	8	1	2	185	6.25
2093	8	1	3	211	7.18
2093	8	1	4	146	4.81
2093	8	1	6	105	3.89
2093	8	1	8	72.7	2.88
2093	8	1	12	40.6	2.11
2093	8	1	16	139	4.71
2093	8	2	24*	67.2	2.89
2093	8	4	0	103	4.55
2093	8	3	48*	76.8	3.85
2093	8	5	0	120	5.83
2093	8	6	0	128	5.96

Subject ID	Treatment ID	Study Day	Nominal Time (hr)	LB-102 Conc. (ng/mL)	LB-101 Conc. (ng/mL)
2093	8	6	0.25	124	5.46
2093	8	6	0.50	124	5.58
2093	8	6	1	161	6.57
2093	8	6	2	185	6.83
2093	8	6	4	184	6.05
2093	8	6	8	144	5.52
2093	8	6	12	120	4.91
2093	8	6	12.25	118	5.01
2093	8	6	12.5	121	4.78
2093	8	6	13	151	5.45
2093	8	6	14	196	6.21
2093	8	6	16	220	7.60
2093	8	6	18	172	7.02
2093	8	6	20	153	6.49
2093	8	7	0	130	5.65
2093	8	8	24	85.0	4.19
2093	8	8	32	60.6	2.68
2093	8	9	48	23.3	1.34
2094	8	1	0	BLQ	BLQ
2094	8	1	0.25	BLQ	BLQ
2094	8	1	0.50	216	2.75
2094	8	1	0.75	327	9.85
2094	8	1	1	343	12.9
2094	8	1	1.5	386	15.1
2094	8	1	2	388	17.0
2094	8	1	3	278	12.8
2094	8	1	4	218	11.1
2094	8	1	6	133	7.77
2094	8	1	8	80.9	5.34
2094	8	1	12	35.7	2.75
2094	8	1	16	188	8.64
2094	8	2	24*	77.4	5.40
2094	8	4	0	102	7.68
2094	8	3	48*	124	8.50
2094	8	5	0	116	8.07
2094	8	6	0	130	9.10
2094	8	6	0.25	130	8.90
2094	8	6	0.50	226	10.7
2094	8	6	1	470	20.2
2094	8	6	2	429	18.2

Subject ID	Treatment ID	Study Day	Nominal Time (hr)	LB-102 Conc. (ng/mL)	LB-101 Conc. (ng/mL)
2094	8	6	4	298	15.6
2094	8	6	8	147	10.1
2094	8	6	12	89.5	6.77
2094	8	6	12.25	95.0	6.32
2094	8	6	12.5	137	7.16
2094	8	6	13	230	9.89
2094	8	6	14	295	13.1
2094	8	6	16	266	14.1
2094	8	6	18	184	11.6
2094	8	6	20	140	9.90
2094	8	7	0	107	7.96
2094	8	8	24	52.3	4.52
2094	8	8	32	39.4	3.41
2094	8	9	48	20.5	1.89
2095	8	1	0	BLQ	BLQ
2095	8	1	0.25	BLQ	BLQ
2095	8	1	0.50	BLQ	BLQ
2095	8	1	0.75	BLQ	BLQ
2095	8	1	1	BLQ	BLQ
2095	8	1	1.5	BLQ	BLQ
2095	8	1	2	BLQ	BLQ
2095	8	1	3	BLQ	BLQ
2095	8	1	4	BLQ	BLQ
2095	8	1	6	BLQ	BLQ
2095	8	1	8	BLQ	BLQ
2095	8	1	12	BLQ	BLQ
2095	8	1	16	BLQ	BLQ
2095	8	2	24*	BLQ	BLQ
2095	8	4	0	BLQ	BLQ
2095	8	3	48*	BLQ	BLQ
2095	8	5	0	BLQ	BLQ
2095	8	6	0	BLQ	BLQ
2095	8	6	0.25	BLQ	BLQ
2095	8	6	0.50	BLQ	BLQ
2095	8	6	1	BLQ	BLQ
2095	8	6	2	BLQ	BLQ
2095	8	6	4	BLQ	BLQ
2095	8	6	8	BLQ	BLQ
2095	8	6	12	BLQ	BLQ
2095	8	6	12.25	BLQ	BLQ

Subject ID	Treatment ID	Study Day	Nominal Time (hr)	LB-102 Conc. (ng/mL)	LB-101 Conc. (ng/mL)
2095	8	6	12.5	BLQ	BLQ
2095	8	6	13	BLQ	BLQ
2095	8	6	14	BLQ	BLQ
2095	8	6	16	BLQ	BLQ
2095	8	6	18	BLQ	BLQ
2095	8	6	20	BLQ	BLQ
2095	8	7	0	BLQ	BLQ
2095	8	8	24	BLQ	BLQ
2095	8	8	32	BLQ	BLQ
2095	8	9	48	BLQ	BLQ
2102	8	1	0	BLQ	BLQ
2102	8	1	0.25	BLQ	BLQ
2102	8	1	0.50	120	1.04
2102	8	1	0.75	182	3.56
2102	8	1	1	126	3.67
2102	8	1	1.5	114	3.47
2102	8	1	2	113	3.16
2102	8	1	3	232	5.94
2102	8	1	4	157	4.05
2102	8	1	6	119	3.42
2102	8	1	8	79.7	2.65
2102	8	1	12	45.9	1.78
2102	8	1	16	131	3.70
2102	8	2	24*	70.9	2.63
2102	8	4	0	124	5.16
2102	8	3	48*	102	4.02
2102	8	5	0	81.6	3.41
2102	8	6	0	116	4.23
2102	8	6	0.25	111	4.28
2102	8	6	0.50	134	4.50
2102	8	6	1	381	9.36
2102	8	6	2	330	7.96
2102	8	6	4	246	7.06
2102	8	6	8	152	5.36
2102	8	6	12	109	4.49
2102	8	6	12.25	111	4.47
2102	8	6	12.5	106	4.13
2102	8	6	13	122	4.19
2102	8	6	14	263	6.46
2102	8	6	16	237	7.83

Subject ID	Treatment ID	Study Day	Nominal Time (hr)	LB-102 Conc. (ng/mL)	LB-101 Conc. (ng/mL)
2102	8	6	18	189	6.52
2102	8	6	20	156	5.41
2102	8	7	0	125	5.02
2102	8	8	24	59.4	3.02
2102	8	8	32	35.1	1.85
2102	8	9	48	14.8	BLQ

BLQ: Below limit quantitation (LB-102 and LB-101 Conc. < 1.00 ng/mL)
* Sample was received as Day 2 24hr or Day 3 48hr. Update from data management changed to Day 2 0hr (pre-dose) and Day 3 0hr (pre-dose).

Table 9: Re-assay of LB-102 in Human Plasma Samples

Subject	Treatment	Time	Original Conc. (ng/mL)	Original Curve No.	Reason for Re-assay	Re-assay Conc. (ng/mL)	Re-assay Curve No.	Reported Conc. (ng/mL)	Reason for Reported Conc.
0007	1	D1, 1.5hr	292	2	1	284 289	3, 3	292	1
0010	1	D1, 1.5hr	BLQ	2	2	BLQ, BLQ	3, 3	BLQ	1
0116	4	D1, 1.5hr	ALQ	9	3	1300	10	1300	2
0116	4	D1, 2hr	ALQ	9	3	1200	10	1200	2
0119	4	D1, 1.5hr	ALQ	9	3	1290	10	1290	2
0119	4	D1, 2hr	ALQ	9	3	1060	10	1060	2
0168	5	D2, 32hr	BLQ	13	2	BLQ, BLQ	14, 14	BLQ	1
0169	5	D2, 32hr	16.2	13	4	16.7 16.5	14, 14	16.2	1

Reasons for Re-assay:
1) Non-quantifiable results expected but quantifiable
2) Quantifiable results expected but not quantifiable
3) ALQ sample will be diluted
4) Unexpected quantifiable results in control sample
Reason for Reported Conc.:
1) Original result was accepted
2) Sample was diluted into calibration range

Table 10: Re-assay of LB-101 in Human Plasma Samples

Subject	Treatment	Time	Original Conc. (ng/mL)	Original Curve No.	Reason for Re-assay	Re-assay Conc. (ng/mL)	Re-assay Curve No.	Reported Conc. (ng/mL)	Reason for Reported Conc.
0007	1	D1, 1.5hr	6.47	2	1	6.04, 6.18	3, 3	6.47	1
0010	1	D1, 1.5hr	BLQ	2	2	BLQ, BLQ	3, 3	BLQ	1
0168	5	D2, 32hr	BLQ	13	2	BLQ, BLQ	14, 14	BLQ	1
0169	5	D2, 32hr	1.69	13	3	1.72, 1.70	14, 14	1.69	1

Reasons for Re-assay:
1) Non-quantifiable results expected but quantifiable
2) Quantifiable results expected but not quantifiable
3) Unexpected quantifiable results in control sample
Reason for Reported Conc.:
1) Original result accepted

Table 11: Incurred Sample Reanalysis (ISR) Results of LB-102 in Human Plasma Samples

Subject ID	Study Day	Time Point (hr)	LB-102 Original Conc. (ng/mL)	LB-102 Reanalysis Conc. (ng/mL)	%Difference*	Flag
0003	1	1.5	112	106	-5.5	
0003	1	12	52.4	50.9	-2.9	
0003	1	2	103	102	-1.0	
0003	1	3	173	175	1.1	
0003	1	4	156	151	-3.3	
0003	1	6	110	113	2.7	
0003	1	8	78.2	77.4	-1.0	
0008	1	1.5	70.9	72.8	2.6	
0008	1	1	152	146	-4.0	
0008	1	2	252	250	-0.8	
0008	1	3	201	200	-0.5	
0008	1	4	159	161	1.3	
0008	1	6	99.5	91.0	-8.9	
0103	1	0.75	267	268	0.4	
0103	1	1.5	816	778	-4.8	
0103	1	12	109	107	-1.9	
0103	1	16	76.0	75.5	-0.7	
0103	1	1	702	679	-3.3	
0103	1	2	641	643	0.3	
0103	1	3	856	827	-3.4	
0103	1	4	577	569	-1.4	
0103	1	6	345	347	0.6	
0103	1	8	231	226	-2.2	
0103	2	24	48.7	47.4	-2.7	
0104	1	0.5	350	361	3.1	
0104	1	0.75	688	680	-1.2	
0104	1	1.5	569	538	-5.6	
0104	1	12	152	151	-0.7	
0104	1	16	104	102	-1.9	
0104	1	1	636	638	0.3	
0104	1	2	738	712	-3.6	
0104	1	3	737	731	-0.8	
0104	1	4	520	526	1.1	
0104	1	6	351	343	-2.3	
0104	1	8	243	231	-5.1	
0104	2	24	66.5	64.0	-3.8	
0109	1	12	172	172	0.0	
0109	1	1	573	551	-3.9	
0109	1	2	637	641	0.6	
0109	1	3	794	776	-2.3	

Subject ID	Study Day	Time Point (hr)	LB-102 Original Conc. (ng/mL)	LB-102 Reanalysis Conc. (ng/mL)	%Difference*	Flag
0109	1	4	605	595	-1.7	
0109	1	6	419	429	2.4	
0109	1	8	289	285	-1.4	
0116	1	0.5	623	592	-5.1	
0116	1	0.75	605	624	3.1	
0116	1	12	95.1	91.1	-4.3	
0116	1	16	55.6	56.8	2.1	
0116	1	1	650	640	-1.6	
0116	1	4	615	620	0.8	
0116	1	6	356	355	-0.3	
0116	1	8	203	205	1.0	
0116	2	24	43.3	41.9	-3.3	
0116	2	32	33.9	33.3	-1.8	
0120	1	0.5	545	534	-2.0	
0120	1	0.75	478	465	-2.8	
0120	1	1.5	687	709	3.2	
0120	1	12	109	109	0.0	
0120	1	16	69.0	64.8	-6.3	
0120	1	1	491	486	-1.0	
0120	1	2	766	757	-1.2	
0120	1	3	771	717	-7.3	
0120	1	4	554	571	3.0	
0120	1	6	313	310	-1.0	
0120	1	8	198	196	-1.0	
0120	2	24	51.4	48.3	-6.2	
2080	1	0.75	264	265	0.4	
2080	1	1.5	289	277	-4.2	
2080	1	16	289	278	-3.9	
2080	1	1	263	256	-2.7	
2080	1	2	278	268	-3.7	
2080	1	3	314	297	-5.6	
2080	1	4	270	266	-1.5	
2080	1	6	160	161	0.6	
2080	1	8	98.8	99.6	0.8	
2080	2	24	96.5	92.3	-4.4	
2080	3	48	164	159	-3.1	
2080	4	0	181	176	-2.8	
2080	5	0	172	172	0.0	
2080	6	0.25	139	137	-1.4	
2080	6	0.5	230	210	-9.1	
2080	6	0	152	142	-6.8	
2080	6	12.25	128	124	-3.2	

Subject ID	Study Day	Time Point (hr)	LB-102 Original Conc. (ng/mL)	LB-102 Reanalysis Conc. (ng/mL)	%Difference*	Flag
2080	6	12.5	134	124	-7.8	
2080	6	12	129	128	-0.8	
2080	6	13	385	359	-7.0	
2080	6	14	568	535	-6.0	
2080	6	16	379	385	1.6	
2080	6	18	273	262	-4.1	
2080	6	1	458	448	-2.2	
2080	6	20	230	213	-7.7	
2080	6	2	511	496	-3.0	
2080	6	4	331	324	-2.1	
2080	6	8	199	202	1.5	
2080	7	0	154	152	-1.3	
2087	3	48	85.2	83.8	-1.7	
2087	4	0	93.3	91.1	-2.4	
2087	5	0	80.2	71.2	-11.9	
2087	6	0.25	86.0	80.8	-6.2	
2087	6	0.5	87.2	87.9	0.8	
2087	6	0	89.6	86.2	-3.9	
2087	6	12.25	68.3	67.4	-1.3	
2087	6	12.5	83.2	81.7	-1.8	
2087	6	12	72.9	70.9	-2.8	
2087	6	13	126	124	-1.6	
2087	6	14	191	187	-2.1	
2087	6	16	201	194	-3.5	
2087	6	18	150	146	-2.7	
2087	6	1	156	151	-3.3	
2087	6	20	115	114	-0.9	
2087	6	2	217	214	-1.4	
2087	6	4	249	244	-2.0	
2087	6	8	120	120	0.0	
2087	7	0	83.7	84.1	0.5	
2094	4	0	102	102	0.0	
2094	5	0	116	113	-2.6	
2094	6	0.25	130	133	2.3	
2094	6	0.5	226	216	-4.5	
2094	6	0	130	132	1.5	
2094	6	12.25	95.0	95.7	0.7	
2094	6	12.5	137	134	-2.2	
2094	6	12	89.5	91.2	1.9	
2094	6	13	230	237	3.0	
2094	6	14	295	304	3.0	
2094	6	16	266	267	0.4	

Subject ID	Study Day	Time Point (hr)	LB-102 Original Conc. (ng/mL)	LB-102 Reanalysis Conc. (ng/mL)	%Difference*	Flag
2094	6	18	184	182	-1.1	
2094	6	1	470	464	-1.3	
2094	6	20	140	143	2.1	
2094	6	2	429	422	-1.6	
2094	6	4	298	306	2.6	
2094	6	8	147	153	4.0	
2094	7	0	107	108	0.9	
2094	8	24	52.3	53.7	2.6	

* %Difference = (Reanalysis Conc. - Original Conc.)/(Mean of Original Conc. and Reanalysis Conc.) x 100%

100% (132 of 132) of results agreed within ±20% of the mean results

Table 12: Incurred Sample Reanalysis (ISR) Results of LB-101 in Human Plasma Samples

Subject ID	Study Day	Time Point (hr)	LB-101 Original Conc. (ng/mL)	LB-101 Reanalysis Conc. (ng/mL)	%Difference*	Flag
0003	1	1.5	2.71	2.54	-6.5	
0003	1	12	1.91	1.86	-2.7	
0003	1	2	2.45	2.36	-3.7	
0003	1	3	3.99	3.92	-1.8	
0003	1	4	3.78	3.65	-3.5	
0003	1	6	2.98	2.97	-0.3	
0003	1	8	2.13	2.02	-5.3	
0008	1	1.5	1.14	1.07	-6.3	
0008	1	1	3.06	2.71	-12.1	
0008	1	2	7.28	6.64	-9.2	
0008	1	3	5.80	5.92	2.0	
0008	1	4	5.03	4.68	-7.2	
0008	1	6	3.71	3.07	-18.9	
0103	1	0.75	4.78	4.62	-3.4	
0103	1	1.5	24.1	23.2	-3.8	
0103	1	12	6.02	5.72	-5.1	
0103	1	16	4.82	4.64	-3.8	
0103	1	1	15.2	14.7	-3.3	
0103	1	2	19.8	19.8	0.0	
0103	1	3	24.6	22.8	-7.6	
0103	1	4	18.9	18.8	-0.5	
0103	1	6	13.4	13.8	2.9	
0103	1	8	10.9	9.78	-10.8	
0103	2	24	2.93	2.87	-2.1	
0104	1	0.5	3.41	3.32	-2.7	
0104	1	0.75	17.2	16.1	-6.6	
0104	1	1.5	16.4	15.7	-4.4	
0104	1	12	6.95	6.81	-2.0	
0104	1	16	4.86	4.78	-1.7	
0104	1	1	17.2	17.7	2.9	
0104	1	2	20.2	19.5	-3.5	
0104	1	3	21.9	21.3	-2.8	
0104	1	4	15.8	15.9	0.6	
0104	1	6	12.3	11.5	-6.7	
0104	1	8	9.51	9.76	2.6	
0104	2	24	3.49	3.35	-4.1	
0109	1	12	2.62	2.59	-1.2	
0109	1	1	3.62	3.45	-4.8	
0109	1	2	6.32	6.27	-0.8	
0109	1	3	7.41	7.34	-0.9	
0109	1	4	5.96	5.67	-5.0	

Subject ID	Study Day	Time Point (hr)	LB-101 Original Conc. (ng/mL)	LB-101 Reanalysis Conc. (ng/mL)	%Difference*	Flag
0109	1	6	4.48	4.37	-2.5	
0109	1	8	3.62	3.56	-1.7	
0116	1	0.5	11.1	11.3	1.8	
0116	1	0.75	37.2	38.4	3.2	
0116	1	12	7.41	7.42	0.1	
0116	1	16	4.98	4.64	-7.1	
0116	1	1	34.8	34.0	-2.3	
0116	1	4	37.4	37.8	1.1	
0116	1	6	24.0	23.2	-3.4	
0116	1	8	13.8	14.3	3.6	
0116	2	24	3.60	3.63	0.8	
0116	2	32	2.38	2.41	1.3	
0120	1	0.5	9.80	10.2	4.0	
0120	1	0.75	13.1	13.5	3.0	
0120	1	1.5	17.4	17.2	-1.2	
0120	1	12	5.64	5.96	5.5	
0120	1	16	4.24	3.95	-7.1	
0120	1	1	13.1	12.7	-3.1	
0120	1	2	21.8	21.6	-0.9	
0120	1	3	21.8	20.4	-6.6	
0120	1	4	17.0	17.7	4.0	
0120	1	6	12.1	11.7	-3.4	
0120	1	8	8.62	8.90	3.2	
0120	2	24	2.88	2.66	-7.9	
2080	1	0.75	5.85	5.74	-1.9	
2080	1	1.5	9.44	9.59	1.6	
2080	1	16	11.1	10.9	-1.8	
2080	1	1	8.83	8.36	-5.5	
2080	1	2	9.37	9.07	-3.3	
2080	1	3	9.43	9.20	-2.5	
2080	1	4	8.86	8.76	-1.1	
2080	1	6	6.45	6.74	4.4	
2080	1	8	4.61	4.49	-2.6	
2080	2	24	5.98	5.63	-6.0	
2080	3	48	9.98	9.57	-4.2	
2080	4	0	10.5	9.98	-5.1	
2080	5	0	11.2	11.1	-0.9	
2080	6	0.25	10.1	9.40	-7.2	
2080	6	0.5	11.8	11.4	-3.4	
2080	6	0	10.4	10.0	-3.9	
2080	6	12.25	7.73	7.59	-1.8	
2080	6	12.5	8.18	7.77	-5.1	

Subject ID	Study Day	Time Point (hr)	LB-101 Original Conc. (ng/mL)	LB-101 Reanalysis Conc. (ng/mL)	%Difference*	Flag
2080	6	12	8.55	8.27	-3.3	
2080	6	13	13.4	12.8	-4.6	
2080	6	14	21.7	20.4	-6.2	
2080	6	16	18.6	17.9	-3.8	
2080	6	18	14.7	15.0	2.0	
2080	6	1	19.7	18.5	-6.3	
2080	6	20	13.4	12.5	-6.9	
2080	6	2	19.2	18.3	-4.8	
2080	6	4	16.6	16.1	-3.1	
2080	6	8	12.0	11.4	-5.1	
2080	7	0	9.94	9.88	-0.6	
2087	3	48	4.53	4.50	-0.7	
2087	4	0	4.89	4.74	-3.1	
2087	5	0	4.34	3.90	-10.7	
2087	6	0.25	4.67	4.22	-10.1	
2087	6	0.5	4.57	4.54	-0.7	
2087	6	0	4.63	4.65	0.4	
2087	6	12.25	3.32	3.27	-1.5	
2087	6	12.5	3.74	3.38	-10.1	
2087	6	12	3.65	3.64	-0.3	
2087	6	13	4.76	4.63	-2.8	
2087	6	14	5.95	5.75	-3.4	
2087	6	16	6.53	6.51	-0.3	
2087	6	18	5.71	5.35	-6.5	
2087	6	1	6.22	6.04	-2.9	
2087	6	20	4.80	4.75	-1.0	
2087	6	2	7.15	7.15	0.0	
2087	6	4	8.20	8.10	-1.2	
2087	6	8	4.63	4.69	1.3	
2087	7	0	4.02	3.81	-5.4	
2094	4	0	7.68	7.67	-0.1	
2094	5	0	8.07	8.10	0.4	
2094	6	0.25	8.90	9.14	2.7	
2094	6	0.5	10.7	10.3	-3.8	
2094	6	0	9.10	8.88	-2.4	
2094	6	12.25	6.32	6.52	3.1	
2094	6	12.5	7.16	7.02	-2.0	
2094	6	12	6.77	6.62	-2.2	
2094	6	13	9.89	9.93	0.4	
2094	6	14	13.1	13.2	0.8	
2094	6	16	14.1	13.4	-5.1	
2094	6	18	11.6	11.6	0.0	

Subject ID	Study Day	Time Point (hr)	LB-101 Original Conc. (ng/mL)	LB-101 Reanalysis Conc. (ng/mL)	%Difference*	Flag
2094	6	1	20.2	19.3	-4.6	
2094	6	20	9.90	9.50	-4.1	
2094	6	2	18.2	17.5	-3.9	
2094	6	4	15.6	15.8	1.3	
2094	6	8	10.1	9.76	-3.4	
2094	7	0	7.96	7.65	-4.0	
2094	8	24	4.52	4.54	0.4	

* %Difference = (Reanalysis Conc. - Original Conc.)/(Mean of Original Conc. and Reanalysis Conc.) x 100%

100% (132 of 132) of results agreed within ±20% of the mean results

9. FIGURES

Figure 1: Typical Calibration Standard Curve for LB-102 in Human Plasma



Figure 2: Typical Calibration Standard Curve for LB-101 in Human Plasma



Figure 3: Representative LC-MS/MS Chromatogram of LB-102 from an Extracted Blank Plasma Sample



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 4: Representative Chromatogram of LB-102 from an Extracted Zero Plasma Sample (Blank + IS)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 5: Representative Chromatogram of LB-102 from an Extracted LLOQ Plasma Sample (Std 1)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 6: Representative Chromatogram of LB-102 from an Extracted ULOQ Plasma Sample (Std 8)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 7: Representative Chromatogram of LB-102 from an Extracted LQC Plasma Sample



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 8: Representative Chromatogram of LB-102 from an Extracted MQC Plasma Sample



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 9: Representative Chromatogram of LB-102 from an Extracted HQC Plasma Sample



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 10: Representative LC-MS/MS Chromatogram of LB-101 from an Extracted Blank Plasma Sample



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 11: Representative Chromatogram of LB-101 from an Extracted Zero Plasma Sample (Blank + IS)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 12: Representative Chromatogram of LB-101 from an Extracted LLOQ Plasma Sample (Std 1)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 13: Representative Chromatogram of LB-101 from an Extracted ULOQ Plasma Sample (Std 8)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 14: Representative Chromatogram of LB-101 from an Extracted LQC Plasma Sample



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 15: Representative Chromatogram of LB-101 from an Extracted MQC Plasma Sample



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 16: Representative Chromatogram of LB-101 from an Extracted HQC Plasma Sample



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 17: LB-102 LQC Performance (3.00 ng/mL ±15%)



Figure 18: LB-102 MQC Performance (30.0 ng/mL ±15%)



Figure 19: LB-102 HQC Performance (750 ng/mL ±15%)



Figure 20: LB-101 LQC Performance (3.00 ng/mL ± 15%)



Figure 21: LB-101 MQC Performance (30.0 ng/mL ±15%)



Figure 22: LB-101 HQC Performance (750 ng/mL ±15%)



Figure 23: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2093, D1, Pre-dose)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 24: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2093, D1, 0.25hr)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 25: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2093, D1, 0.5hr)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 26: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2093, D1, 0.75hr)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 27: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2093, D1, 1hr)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 28: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2093, D1, 1.5hr)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 29: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2093, D1, 2hr)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 30: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2093, D1, 3hr)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 31: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2093, D1, 4hr)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 32: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2093, D1, 6hr)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 33: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2093, D1, 8hr)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 34: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2093, D1, 12hr)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 35: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2093, D1, 16hr)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 36: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2093, D2, 24hr)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 37: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2093, D3, 48hr)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 38: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2093, D4, Pre-dose)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 39: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2093, D5, Pre-dose)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 40: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2093, D6, Pre-dose)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 41: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2093, D6, 0.25hr)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 42: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2093, D6, 0.5hr)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 43: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2093, D6, 1hr)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 44: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2093, D6, 2hr)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 45: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2093, D6, 4hr)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 46: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2093, D6, 8hr)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 47: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2093, D6, 12hr)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 48: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2093, D6, 12.25hr)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 49: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2093, D6, 12.5hr)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 50: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2093, D6, 13hr)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 51: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2093, D6, 14hr)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 52: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2093, D6, 16hr)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 53: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2093, D6, 18hr)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 54: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2093, D6, 20hr)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 55: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2093, D7, Pre-dose)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 56: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2093, D8, 24hr)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 57: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2093, D8, 32hr)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 58: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2093, D9, 48hr)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 59: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2094, D1, Pre-dose)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 60: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2094, D1, 0.25hr)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 61: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2094, D1, 0.5hr)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 62: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2094, D1, 0.75hr)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 63: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2094, D1, 1hr)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 64: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2094, D1, 1.5hr)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 65: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2094, D1, 2hr)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 66: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2094, D1, 3hr)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 67: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2094, D1, 4hr)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 68: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2094, D1, 6hr)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 69: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2094, D1, 8hr)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 70: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2094, D1, 12hr)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 71: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2094, D1, 16hr)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 72: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2094, D2, 24hr)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 73: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2094, D3, 48hr)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 74: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2094, D4, Pre-dose)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 75: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2094, D5, Pre-dose)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 76: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2094, D6, Pre-dose)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 77: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2094, D6, 0.25hr)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 78: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2094, D6, 0.5hr)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 79: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2094, D6, 1hr)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 80: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2094, D6, 2hr)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 81: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2094, D6, 4hr)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 82: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2094, D6, 8hr)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 83: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2094, D6, 12hr)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 84: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2094, D6, 12.25hr)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 85: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2094, D6, 12.5hr)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 86: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2094, D6, 13hr)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 87: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2094, D6, 14hr)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 88: Example Chromatogram of LB-102 from an Extracted Plasma Sample (2094, D6, 16hr)



Upper: LB-102; Lower: LB-102-d_5 (IS)

Figure 89: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2093, D1, Pre-dose)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 90: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2093, D1, 0.25hr)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 91: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2093, D1, 0.5hr)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 92: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2093, D1, 0.75hr)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 93: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2093, D1, 1hr)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 94: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2093, D1, 1.5hr)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 95: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2093, D1, 2hr)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 96: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2093, D1, 3hr)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 97: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2093, D1, 4hr)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 98: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2093, D1, 6hr)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 99: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2093, D1, 8hr)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 100: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2093, D1, 12hr)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 101: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2093, D1, 16hr)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 102: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2093, D2, 24hr)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 103: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2093, D3, 48hr)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 104: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2093, D4, Pre-dose)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 105: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2093, D5, Pre-dose)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 106: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2093, D6, Pre-dose)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 107: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2093, D6, 0.25hr)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 108: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2093, D6, 0.5hr)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 109: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2093, D6, 1hr)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 110: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2093, D6, 2hr)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 111: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2093, D6, 4hr)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 112: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2093, D6, 8hr)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 113: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2093, D6, 12hr)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 114: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2093, D6, 12.25hr)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 115: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2093, D6, 12.5hr)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 116: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2093, D6, 13hr)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 117: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2093, D6, 14hr)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 118: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2093, D6, 16hr)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 119: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2093, D6, 18hr)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 120: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2093, D6, 20hr)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 121: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2093, D7, Pre-dose)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 122: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2093, D8, 24hr)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 123: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2093, D8, 32hr)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 124: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2093, D9, 48hr)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 125: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2094, D1, Pre-dose)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 126: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2094, D1, 0.25hr)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 127: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2094, D1, 0.5hr)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 128: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2094, D1, 0.75hr)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 129: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2094, D1, 1hr)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 130: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2094, D1, 1.5hr)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 131: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2094, D1, 2hr)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 132: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2094, D1, 3hr)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 133: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2094, D1, 4hr)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 134: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2094, D1, 6hr)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 135: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2094, D1, 8hr)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 136: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2094, D1, 12hr)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 137: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2094, D1, 16hr)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 138: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2094, D2, 24hr)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 139: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2094, D3, 48hr)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 140: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2094, D4, Pre-dose)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 141: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2094, D5, Pre-dose)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 142: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2094, D6, Pre-dose)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 143: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2094, D6, 0.25hr)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 144: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2094, D6, 0.5hr)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 145: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2094, D6, 1hr)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 146: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2094, D6, 2hr)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 147: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2094, D6, 4hr)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 148: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2094, D6, 8hr)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 149: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2094, D6, 12hr)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 150: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2094, D6, 12.25hr)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 151: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2094, D6, 12.5hr)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 152: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2094, D6, 13hr)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 153: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2094, D6, 14hr)



Upper: LB-101; Lower: LB-101-d_5 (IS)

Figure 154: Example Chromatogram of LB-101 from an Extracted Plasma Sample (2094, D6, 16hr)



Upper: LB-101; Lower: LB-101-d_5 (IS)